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The acquisition of and departure from stemness in cancer tissues might not only be
hardwired by genetic controllers, but also by the pivotal regulatory role of the cellular
metabotype, which may act as a “starter dough” for cancer stemness traits. We have
coined the term metabostemness to refer to the metabolic parameters causally controlling
or functionally substituting the epitranscriptional orchestration of the genetic reprogram-
ing that redirects normal and tumor cells toward less-differentiated cancer stem cell (CSC)
cellular states. Certain metabotypic alterations might operate as pivotal molecular events
rendering a cell of origin susceptible to epigenetic rewiring required for the acquisition of
aberrant stemness and, concurrently, of refractoriness to differentiation.The metabostem-
ness attribute can remove, diminish, or modify the nature of molecular barriers present
in Waddington’s epigenetic landscapes, thus allowing differentiated cells to more easily
(re)-enter into CSC cellular macrostates. Activation of the metabostemness trait can poise
cells with chromatin states competent for rapid dedifferentiation while concomitantly set-
ting the idoneous metabolic stage for later reprograming stimuli to finish the journey from
non-cancerous into tumor-initiating cells. Because only a few permitted metabotypes will be
compatible with the operational properties owned by CSC cellular states, the metabostem-
ness property provides a new framework through which to pharmacologically resolve the
apparently impossible problem of discovering drugs aimed to target the molecular biology
of the cancer stemness itself. The metabostemness cancer hallmark generates a shift-
ing oncology theory that should guide a new era of metabolo-epigenetic cancer precision
medicine.
Keywords: stemness, metabolism, reprograming, cancer stem cells, oncometabolites, Waddington, epigenetic
landscapes
INTRODUCTION
We are accumulating ever-growing evidence that metabolism and
stemness are highly intertwined processes in tumor tissues. Can-
cer is beginning to be understood as a disease of reprograming
that appears to involve the progressive resetting of the metabolic
infrastructure and metabolite levels concomitantly with changes
in cellular differentiation (1–9). The modulation of metabo-
lism and associated signaling is being increasingly implicated
in the determination of cell identity during nuclear reprogram-
ing and oncogenesis. The transformation of cellular metabolism
precedes changes in stemness and, therefore, metabolic repro-
graming appears to reflect the molecular dynamics fundamental
for the rearranging and redirection of cell-fate (10–30). More-
over, we have recently learned that certain metabolites can be
oncogenic themselves and, crucially, the malignant activity of
these oncometabolites, i.e., small-molecule components (or enan-
tiomers) of normal metabolism whose accumulation causes sig-
naling dysregulation to establish a milieu that initiates and drives
carcinogenesis (31–45) likely relies on their ability to epigenetically
block the acquisition of differentiation markers while inducing the
expression of stem cell maintenance genes. A key question, how-
ever, remains unanswered: how can metabolism and metabolites
exert influence over the transcriptional factors, the chromatin
structure, and the epigenetic circuits that establish and maintain
the self-renewal and differentiation capacities owned by cancer
stem cells (CSCs), which are suggested to drive tumor-initiation
and metastatic progression?
Herein, we propose that the molecular logic behind the con-
version of non-CSCs into CSCs can be better understood in terms
of cellular metabotypes that operate as pathways or roadblocks
by facilitating or impeding, respectively, the epitranscriptional
orchestration of the genetic reprograming that drives the intrinsic
and microenvironmental paths to CSC cellular states. We therefore
postulate that a bona fide metabolo-epigenetic reprograming of
stemness exists in pre-malignant and cancer tissues, a new cancer
trait to which we have coined the name “metabostemness.”
METABOLISM: EMERGING AS A CANCER HALLMARK
When Hanahan and Weinberg revisited the hallmarks of cancer
in 2011 (46), they raised the question of whether the deregulation
of cellular metabolism in tumor tissues might be viewed as a core
hallmark capability of cancer cells that is as fundamental as the six
well-established core hallmarks formerly proposed in 2000 (47).
Alternatively, the reprograming of cancer metabolism might be
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merely viewed as an evolutionary conserved target that is upstream
programed by oncogenic gain-of-function events and the loss of
tumor-suppressors (48). The latter view implies that a stereo-
typed pattern of cancer-associated metabolic changes including
accelerated glucose transport, reduced mitochondrial oxidative
phosphorylation (OXPHOS) accompanied by aerobic glycolysis
and lactate production (i.e., the Warburg effect), and augmented
de novo fatty acid biogenesis (i.e., the lipogenic phenotype), can be
all induced by most common genetic alterations in the oncogenic
PI3K/AKT/mTOR/HIF axis and in the tumor-suppressor p53 sys-
tem (49–53). Not surprisingly, the metabolic signatures of cancer
cells have been frequently perceived by traditional biochemists
as indirect, secondary phenomena that are merely required to
support oncogene-directed anabolic proliferation and survival.
Instead of adopting the challenging notion that tumor cells might
essentially exhibit increased autonomy in maintaining an anabolic
phenotype because proto-oncogenes and tumor-suppressors orig-
inated through evolution as components of metabolic regulation,
Hanahan and Weinberg rather considered cluster analyses showing
that several cancer-driving mutations converge on metabolic path-
ways. Subsequently, they designed cancer metabolic reprograming
as an “emerging hallmark” to highlight the unresolved issues sur-
rounding its functional independence from the bona fide cancer
hallmarks (46, 47).
STEMNESS: A FORGOTTEN CORE CANCER CAPABILITY
Several researchers have advocated incorporating the two key
properties of stem cells, i.e., the ability to proliferate without lin-
eage commitment (i.e., self-renewal), and the capacity to differen-
tiate into one or more specialized cell types (i.e., pluripotency), as a
new-dimensional hallmark of cancer (54–58). The role of stemness
as a cancer attribute was originally identified from the analy-
sis of the outcomes of high-throughput gene expression datasets
revealing that biologically aggressive, poorly differentiated tumors
display transcriptional profiles characterized by the overrepresen-
tation of gene signatures usually enriched in embryonic stem cells
(ESCs) (59–63). Some carcinomas appear to hijack the stemness
transcriptional factors’ machinery to support tumor-initiation,
aberrant proliferation, and metastasis; accordingly, the activa-
tion of reprograming-like dedifferentiation mechanisms driven
by master regulators of self-renewal and pluripotency (e.g., Sox2,
Oct4, and Lin28) has been repeatedly shown to generate cell popu-
lations enriched with CSC-like cells that possess tumor-initiation
and colonization capacities (64–72). However, the pioneer sug-
gestion by Bond et al. (73) almost 20 years ago that the apparent
dedifferentiation accompanying malignant progression can play
a causal rather than passive role in the critical tumors-behavior-
switch from well-differentiated to highly aggressive forms has been
commonly forgotten. Most cancer researchers have adopted an
alternative view, in which tumors adhere to essentially irreversible
top-down hierarchies of CSC-driven cellular differentiation that
caricature those occurring in normal tissues. As for metabolic
reprograming, the stemness-related loss of differentiation, one
fundamental characteristic of most tumor tissues, was not consid-
ered a distinct hallmark in the framework provided by Hanahan
and Weinberg in 2011.
STEMNESS IN CANCER TISSUES: WHAT IS THE ORIGIN OF
CANCER STEM CELLS?
Carcinogenesis involves the accumulation of numerous muta-
tional events over long periods of time. In tumors that originate
from tissues with high cellular turnover, only adult stem cells
(ASCs), with their innate self-renewal capacity, can remain in the
tissue long enough to accumulate the number of oncogenic alter-
ations that are necessary to support a complete malignant trans-
formation. This has led to the hypothesis that tumor-initiation
and progression are driven by CSCs, commonly defined as the
fraction of tumor cells specifically endowed with self-renewal
and tumor-seeding potential and the ability to spawn non-CSC
progeny (74–76). Not surprisingly, ASCs have been commonly
hypothesized to represent the cells of origin in most tumors
because they can be directly targeted with primary transform-
ing events; more committed progenitors can also similarly gain
the ability of self-renewal and function as CSCs through onco-
genic transformation. In this hierarchical organization with rare,
self-renewing CSCs residing at the top, the disorganized tumoral
mass should be merely viewed as an aberrant version of the
ASC-driven mechanisms that govern the corresponding tissue’s
normal development (77–79). However, while this is the case for
cancers with a stem cell origin such as hematopoietic malignan-
cies, for those with non-stem cell origin including liver, breast,
lung, pancreatic, and prostate cancers, although CSCs obviously
exhibit stem cell properties, they do not necessarily originate
from the direct transformation of normal tissue stem cells or
progenitor cells.
We now know that non-cancerous and differentiated cancer-
ous cells possess enough plasticity to aberrantly reprogram and
acquire bona fide CSC properties. Indeed, the inherent aggressive-
ness of carcinomas appears to derive not from the pre-existing
content of CSCs, but rather from the intrinsic proclivity of a given
tumor tissue to generate new CSC from non-CSC cell populations
(80–90). Such plasticity potential of non-CSCs to acquire a CSC
cellular state depending on their epigenetic/transcriptional signa-
ture and in their interpretation of multiple microenvironmental
signals (e.g., hypoxia, starvation, inflammation, and therapeu-
tics) is fully absent in the conventional depiction of the one-way
stem/progenitor cell hierarchy and is revolutionary changing our
current perception of the CSCs’ biology. By understanding cancer
as a disease of differentiation, CSCs can be generated at any time
during cancer progression so long as appropriate oncogenic lesions
that can enable epigenetic reprograming to a stem-like cellular
state are present or, alternatively, tumor-suppressors are hindered.
Because CSCs are emergent, dynamic cellular states, i.e., CSCs are
also made and not just born, multiple independently derived and
molecularly distinct CSC cell populations may evolve depending
on the likelihood of reprograming phenomena within tumors. The
resulting heterogeneity manifests as diverse clones of CSC that vary
in terms of their dormancy, proliferative, biomarkers, metastatic,
and/or chemo-sensitivity profiles. Indeed, the molecular hetero-
geneity and stochasticity of gene expression in cancer tissues can
drive a continuum of cancer cell states to rapidly shape cancer’s
evolution through a greater probability of entering CSC cellular
states.
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CANCER STEM CELLS REPROGRAMING: A NEW PARADIGM
FOR UNDERSTANDING TUMORS’ SOCIAL STRUCTURE
Cancer stem cell reprograming is a molecular process able to estab-
lish the bidirectional control of tumors’ epigenetic hierarchy. On
the one hand, cancer genetic alterations can reset the epigenetic
and transcriptional status of an initially healthy cell to establish a
newly acquired, pathological differentiation program of aberrant
stemness (i.e., a CSC-like cellular state) that ultimately leads to
cancer development. On the other hand, differentiated tumor cells
can dynamically alter their transcriptional and epigenetic circuits
to acquire a less-differentiated CSC cellular state. Differentiated
(normal and tumor) cells and CSCs are therefore distinct cellular
states that could convert each other to achieve a balanced equilib-
rium within heterogeneous cancer cell populations. Crucially, the
reprograming-differentiation cancer model easily explains many
of the apparently paradoxical aspects of the CSC-related tumor
biology: (1) the apparently contradictory reconciliation of the rar-
ity (of CSC number) with robustness (of CSC properties) in some
tumors; (2) the challenging application of hierarchical models to
some tumors such as metastatic melanoma [i.e., an extreme exam-
ple of stem cell reprograming in which certain epigenetic makeups
endow almost the entire tumor cell population with the easiest
ability to acquire CSC qualities; (91)]; (3) the lack of bona fide CSC
markers enabling the general identification of stemness across dif-
ferent cancer types and even during the natural history of a given
tumor type (61, 92–94); (4) the occurrence of unique stem-like
states due to the continuous evolution and adaptation to new con-
straints [e.g., the conversion of tumor cells into functional vascular
endothelial cells that resist antiangiogenic therapy or the transient
assumption by individual cells of a reversible drug-tolerant state to
protect the cancer cell population from eradication due to poten-
tially lethal exposures; (95, 96)]; and (5) the accumulation of CSCs
following treatment with therapeutics [i.e., cancer therapies do
not necessarily enrich cancer tissues with pre-existing, treatment-
refractory CSCs, as an accelerated production of de novo CSC
cellular states from the residual cancer cells may easily repopulate
their ranks while the older CSCs die; (97)]. The reprograming-
dedifferentiation cancer model illuminates the fact the “hierarchy”
within tumors’ social structure is not rigid because self-renewal
and differentiation are acquired traits. Importantly, CSC repro-
graming does not exclude the pivotal role of non-strictly genetic
factors (e.g., metabolites and microenvironment), which can sig-
nificantly impact the conversion probability between non-CSCs’
and CSCs’ cell stages.
CANCER METABOSTEMNESS: A CONCEPTUAL DESCRIPTION
A key peculiarity of the abovementioned model of stem cell repro-
graming is that the dysregulation of specific signaling pathways,
rather than the type of the cell of origin, dictates the emergence and
phenotype of CSCs in a given tissue. If any differentiated cell can
be reprogramed to an induced pluripotent state through the right
combination of transcription factors, then, following the same line
of reasoning and in theory, non-CSC cells could similarly dediffer-
entiate to a CSC cellular state given that an appropriate stemness
transcription factor is strongly activated. Moreover, by balancing
counteracting differentiation forces (98), reprograming to a CSC
functional state might be also achieved through the establishment
of a fine-tuned equilibrium that might not require of the tradi-
tionally considered master regulators of stemness. However, by
following the numerous parallels between the process of repro-
gramming differentiated cells-to-induced pluripotent stem cells
(iPSCs) and differentiated cells-to-CSCs, when considering the
slow kinetics and efficiencies of iPSCs generation (99) it might
tempting to suggest that not all of the normal or cancerous cells
would possess the equivalent ability ab initio to permit their
successful reprograming to CSC cellular states. Whereas certain
populations are seemingly refractory to reprograming, we now
know that the ability to generate iPSCs is intrinsic to any cell given
sufficient time and the appropriate reprograming push. Thus,
additional expression of the so-called Yamanaka factors, the use
of additional stemness transcription factors, the use of chemicals,
or the direct modification of critical epigenetic components can
greatly enhance (even to efficiencies nearing 100%) and acceler-
ate reprograming to iPSCs (100–104). Ever-growing iPSCs-based
findings showing that metabolic reprograming phenomena might
be essential for transcription factor-induced stemness have further
confirmed that the elaborate regulation of key master metabolic
switches seems to contribute to the metabolic changes that take
place in the transition between a differentiated cell and a stem cell,
to the maintenance of the stemness properties in stem cell cellular
states, and to the exit from the pluripotent state to become primed
for differentiation (10–30, 105). In this scenario, we recently rea-
soned that the dedifferentiation of somatic cells into iPSCs as well
as the de novo generation of CSC cellular states from non-CSCs
may represent mechanistically related, metabolically dependent
reprograming phenomena in which epigenetic remodeling, the
activation of genes related to the establishment and maintenance
of stemness, and/or the scavenging of fate determinants related to
cell differentiation might be co-opted in the absence of functional
tumor-suppressing mechanisms. In other words, the metabolic
infrastructure and functioning might operate as the key molecu-
lar constraint controlling the kinetics of stemness reprograming
for the optimal routing of non-CSC to CSC-like cellular states
during cancer genesis and progression.
We propose that the acquisition of and departure from stem-
ness in pre-malignant and cancer tissues might not be governed
exclusively by genetic and epigenetic controllers, but also by the
pivotal regulatory role of the cellular metabotype, which may act
as “starter dough” for cancer stemness traits. When viewing cancer
stemness as a flexible quality that might be gained and lost in a
metabolic-dependent manner, the cellular metabotype then oper-
ates as a supra-genetic dimension guiding the ability of epigenetic
and transcriptional circuitries to redirect normal and non-CSC
tumor cells toward a CSC-like cellular state. Certain metabo-
typic shifts might function as very early molecular events that
render a (normal or cancerous) differentiated cell more suscep-
tible to transcriptional and epigenetic rewiring required for the
acquisition of aberrant stemness and, concurrently, of refractori-
ness not only to apoptosis, but also to differentiation. Subsequent
hits, occurring in variable orders, combinations, and/or inten-
sities can then confer the definitive quality of cancer stemness
and dictate the dynamic cellular hierarchy within a tumor tis-
sue. We have therefore coined the term “metabostemness” to refer
to the metabolic parameters causally controlling or functionally
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substituting the epitranscriptional orchestration of the genetic
reprograming that redirects normal and non-CSC tumor cells
toward less-differentiated CSC cellular states (Figure 1). As such,
the metabostemness trait can be understood as the physiological
glue that metabolically connects all the omic layers with a self-
autonomous CSC cellular quality; operatively, metabostemness is
a systeomic function of observable metabolic phenotypes (i.e.,
the CSC metabolophenome) that predate systems biology and
its sub-disciplines (i.e., genomics, transcriptomics, proteomics,
and metabolomics) at the level of CSC cellular states. From a
holistic perspective, the metabostemness hallmark comprises the
intrinsically, microenvironmental, and physiologically determined
metabolic parameters that enable the self-renewal and differ-
entiation capacities owned by the CSC cellular states in tumor
tissues (Figure 1). Four main features can conceptually define the
metabostemness property in cancer tissues:
(1) the cellular metabotype determines the global success of the
epitranscriptional reprograming that redirects normal and
non-CSC tumor cells toward less-differentiated CSC cellular
states;
(2) the cellular metabotype imposes the “permitted” and “pro-
tected” cellular modes that allow or prevent, respectively, the
completion of the molecular journey from non-CSC to CSC
cellular states;
(3) the closer a cellular metabotype is to that of a CSC, the higher
its reprograming capacity for acquiring a CSC cellular state;
and
(4) metabolic interventions can reprogram cellular metabotypes
in a manner that successfully impedes the aberrant acquisition
and functioning of stemness in cancer tissues.
CANCER METABOSTEMNESS: AN OPERATIONAL
DELINEATION
Transcription factors are commonly viewed as the key intrinsic
regulators of cell-fate, i.e., the cell-fate choice exclusively involves
modulating networks of transcription factors. It is also generally
accepted that a given cellular type including that of stem cells must
not be excessively sensitive to random, or unpredictable, small
fluctuations in the levels of specific signals. This indispensable
requirement to withstand modulating factors that may perturb
the gene regulatory network (GRN) architecture – i.e., the gene–
gene relationships, their directionality (“who controls whom”),
their interaction modalities (inhibition versus stimulation), and
the modes of cooperation – defines a cell type in a timely man-
ner and strongly limits the number of solutions or “cellular states”
for a given genetic system including those of cancer tissues (106–
108). The evolving dynamics of molecular connections between
the genes and gene products that can interact with each other
within a cell, including the underlying regulatory logic that govern
FIGURE 1 | Metabostemness: a new-dimensional cancer hallmark. We
have recently hypothesized that CSC-driven malignant progression might be
envisioned as an evolving spatio-temporal heterogeneous structure that might
not be driven solely by irreversible genomic hits but also by metabolic means;
thus, the acquisition of, and departure from, stemness in cancer tissues might
be governed not only by transcriptional and epigenetic controllers but also by
the pivotal regulatory role of metabolic reprograming in cell-fate decisions. In
this scenario, we propose the actual existence of a new phenomic cancer
hallmark to which we have coined the term “metabostemness.”
Metabostemness refers to the metabolic parameters at the cell-intrinsic,
tissue-microenvironmental, and systemic levels that enable the unique
functional properties owned by the CSC cellular states. A metabotype-based
infrastructure and functioning of CSC can therefore operate as a supra-genetic
dimension controlling over or functionally substituting the epitranscriptional
orchestration of the genetic reprograming that redirects normal and non-CSC
tumor cells toward less-differentiated CSC cellular states.
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these interactions, must therefore provide robustness with respect
to varying extrinsic signals and intrinsic factors, i.e., the noise.
Such stability of the cell state is obviously required in stem cells
to support the self-renewal and maintenance of an uncommitted
state, but must also afford certain flexibility in the choice of cell-
fate to permit the diversification and differentiation of cell types
in response to intrinsic cues or extrinsic signals.
During normal development, cells make very precise transi-
tions between network states of gene expression patterns, which
must be stable and irreversible in terminally differentiated cells, at
least under homeostatic or physiological conditions. Conversely,
the potential for reverse differentiated-to-stem cell state conver-
sions has been revolutionarily exemplified by the nuclear repro-
graming of somatic cells to a pluripotent stem cell state driven by
a small number of stemness transcription factors. Crucially, a very
similar consideration of cell states transitions apply to pathological
states such as cancer, where the misexpression of transcriptional
regulators can reset the status of an initially healthy cell to establish
a newly acquired, pathological differentiation program of aberrant
stemness that ultimately leads to cancer development. Consider-
ing the above-depicted scenario, it is not surprising that the major
challenge that is being faced by regulatory biology in the postge-
nomic era of understanding cancer diseases is to map the core
transcription factors’networks associated with different cancer cell
types, especially the underlying regulatory logic that governs their
behavior as differentiated versus CSC cellular states. The accurate
delineation of such a map will provide crucial insights into the
rules that define cancer cellular states (i.e., cancer heterogeneity)
and how transitions between cancer cellular states are achieved,
thus providing unforeseen therapeutic solutions to the appar-
ently irresoluble problem of targeting cancer dynamical models
such as the model of reversibility, or cancer cell reprograming, in
which heterogeneous populations of CSC can arise by reversion
of more differentiated cancer cells. Indeed, multiple different CSC
populations have been described for a given cancer type, despite
presenting different gene and protein expression signatures, thus
leading to the currently accepted view that the characterization of
CSCs can no longer be based on marker expression, but instead at
their functional level, strongly supporting the model of reversibil-
ity, or CSC reprograming, in which the populations of CSCs arise
by reversion of more differentiated cells (85, 109–113).
As for bona fide pluripotency, CSCs should be viewed as func-
tional states rather than discrete cellular entities characterized by
well-defined and static gene networks, thus highlighting cancer
stemness as a statistical property resembling a macrostate in sta-
tistical physics (108, 114, 115). If these macrostate entities of func-
tional CSCs are correct, the gene expression signature for a CSC in
a given tumor tissue may be dynamic or non-unique, which can
create a challenge when trying to unambiguously establish math-
ematical frameworks describing CSC reprograming phenomena.
We propose that incorporating metabolism and metabolites into
the intrinsic variability of the CSCs’ epigenetic and genetic sig-
natures can significantly reduce the high-dimensional problem
of understanding reprograming dynamics both at the single-cell
level and the population level. But how can we model the incor-
poration of the metabolism and metabolites into the epigenetic
and genetic signatures accounting for CSC variability during the
generation, maintenance, and evolution of CSC cellular states in
cancer tissues? To definitely consider the process of reprograming
to CSC into a rigorous, quantifiable theory, the establishment of
a mathematical framework able to accurately mapping the land-
scape pertaining the transition between non-CSC and CSC cell
states needs to incorporate a never before considered metabolic
dimension.
DYNAMIC PERSPECTIVE BY DEVELOPING PROBABILISTIC
DESCRIPTIONS OF CELL STATES
Cancer cell states (e.g.,non-CSC versus CSC) can be parameterized
as vectors of molecular characteristics, Ŝ, which are generally con-
sidered a set of gene expression levels
(
Ŝ = [g1, g2, g3, . . . , gN ]
)
(Figure 2). A cancer cell at any time t can exist in a point of
this state space, and its state can change with time in response
to particular cell-autonomous and non-cell-autonomous condi-
tions, i.e., in a CSC reprograming scenario, Ŝ is a function of
time Ŝ(t ) as a result of noise, reprograming, or differentiation. By
plotting one trajectory during a state change from t 0 to t 1, we
can fully describe the transition between cancer cell states during
this time S(t )= [g 1(t ), g 2(t ), g 3(t ), . . . ,gN(t )]. For simplicity, we
show a cancer cell state space generated by the level of N different
genes, g 1 to gN, where each arrow represents an axis correspond-
ing to the expression level of that particular gene transcript. Such
a cancer cell state space provides an accurate means to quantita-
tively organize and visualize different states of a cancer cell with
a fixed genome. Indeed, often cancer cells will cluster in particu-
lar regions of the cancer cell state space, which can be viewed as
stable types of cancer cells that express particular markers. Those
regions where no cancer cells are found correspond to cell states
that are somehow unstable for the given genome of the cancer
cell in the microenvironmental conditions considered. Thus, N is
generally reduced to two to three more manageable dimensions
through statistical techniques [e.g., principal component analy-
sis (PCA)]. Figure 2 shows a two-dimensional representation of
the cancer cell state space, where each axis (ga and gb from PCA)
is a linear combination of genes g 1 to gN and, therefore, stable
types of cancer cells exist at particular points of this graph. By
quantitatively mapping the gene expression levels of a large sam-
ple of single stable cancer cells in the same space, the probability
of occupying each point in this space can be plotted in a contin-
uous fashion, and regions with high densities of spots can define
observable cancer cell types. The continuous probabilistic descrip-
tion of cancer cell types staying at a particular point in state space
can be represented as a landscape, by calculating − ln [P (̂S)] at
each point. In this landscape, V (̂S) represents “energy barriers”
between transitions involving any two cellular states and thus may
provide a more thorough description of non-CSC-to-CSC transi-
tions. However, we should acknowledge that while the nature of
the cancer cell substates can be elucidated in terms of a landscape
picture in which stable differentiated, non-CSC, and CSC cellular
states are mathematically defined as “attractors” – i.e., observable
cancer cell types – the architecture of these apparently stable “net-
work states” is described exclusively in terms of genes, or at the
most epigenetic, expression patterns. Indeed, when selecting a par-
ticular set of characteristics as being informative for the transition
between two cell states of interest, functional cell types are almost
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FIGURE 2 | Metabostemness: developing probabilistic descriptions of non-CSC and CSC cell states. (See text for a more detailed explanation).
exclusively defined based on levels of gene expression changes on
the timescale of days to weeks. In this probabilistic framework,
the genetic background defines the abovementioned architecture
of the cell state space, meaning that particular gene–gene relation-
ships, interaction modalities, and integrating transfer functions
(i.e., the GRN) are largely “hardwired” by the genome. A more
detailed characterization not only of gene expression, but also
of biochemical noise in signaling processes (e.g., binding of epi-
genetic modifiers to particular genome loci, inherent stochastic
nature of molecular binding events, secondary messengers, and
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variable cell–cell contact) and of the epigenetic state (e.g., levels
of epigenetic methylation or acetylation marks on DNA or chro-
matin) is expected to provide more insight into the missing key
parameters and required transcriptional changes controlling the
kinetics of CSC reprograming. In this regard, we propose that the
regulatory network architecture of a cancer landscape comprises
not only the genes and proteins that can interact within a cancer
cell, but also the cellular metabotype, which can necessarily and
sufficiently characterize different functional cell states within het-
erogeneous cancer cell populations through different types and/or
levels of certain metabolites.
But how do metabolism and metabolites hierarchically inte-
grate with genetic expression programs to coordinately regulate
CSC function and fate? Because DNA transcription is regulated by
chromatin organization, the occurrence of metabolic inputs into
epigenetic modifications of chromatin and transcription should
be viewed as the molecular bridge that links metabolism to epige-
netics and gene expression during non-CSC to CSC transitions. We
are accumulating ever-growing evidence suggesting that, beyond
the classically delineated transcriptional output of growth fac-
tor/hormonal signaling pathways, a variety of metabolic signals
can play also critical roles in determining chromatin structure, thus
directly linking metabolic perturbations to the dysregulation of
cellular differentiation (116–118) (Figure 3). Indeed, CSC metab-
olism is linked to epigenetics and gene expression in a multifaceted
and bidirectional manner:
– Metabolic fluxes can be controlled by metabolic enzymes that
are directly regulated by stemness transcription factors such as
c-Myc, which can act both locally and globally on chromatin
to exert wide-ranging effects on the biology of stem and tumor
cells (119–122).
– Epigenetic alterations (e.g., demethylation or methylation of
gene promoter regions, protein acetylation) can contribute to
the deregulated expression of key enzymes involved in cell
metabolism. Thus, the reversible acetylation of histones and
non-histone proteins has been shown to affect cell metabo-
lism, and glycolytic versus OXPHOS pathway gene expression
and DNA methylation patterns change during reprograming
to stemness. The rate-limiting glycolytic enzyme Hexokinase
II (HK2) and the key enzyme of gluconeogenesis fructose-1,6-
biphosphatase (FBP1), with opposing roles in glycolysis, have
recently been identified as epigenetically regulated by promoter
demethylation and methylation, respectively (123–126). PKM2,
which catalyzes the conversion of phosphoenol pyruvate to
pyruvate, is targeted for degradation in a glucose-dependent
manner by acetylation at lysine K305; the epigenetic silencing
of FBP1, which catalyzes the energy-consuming conversion of
fructose-1,6-biphosphate to fructose-6-phosphate, is employed
by CSC as a mechanism of glucose flux maintenance via glycoly-
sis and other associated biosynthetic pathways (127). The tumor
tissues’ extra requirements of glucose, an essential nutrient for
CSC that, when present in the culture environment, signifi-
cantly increases the percentage of CSC-like cells in the overall
cancer cell population (128), can be achieved via the epige-
netic silencing of DERL3, the gene responsible for degrading the
glucose transporter SLC2A1 [glucose transporter 1 (GLUT1)]
(129). Moreover, posttranscriptional modifications of p53, the
key connector of reprograming to pluripotency and tumori-
genesis (130–136), may affect cell metabolism through down-
stream targets such as TIGAR (TP53-induced glycolysis and
apoptosis regulator) and interaction with PGC-1α [peroxiso-
mal proliferator-activated receptor (PPAR) gamma coactivator
1] (137–142).
– Epigenetic modifications of DNA and histones by methyla-
tion and acetylation reactions require cofactors that are derived
from various metabolic pathways including glycolysis, fatty
acid oxidation, tricarboxylic acid (TCA) cycle, and OXPHOS
(Figure 3). Among these cofactors, we can mention the follow-
ing: (a) S-adenosyl-L-methionine (SAM), which is a cofactor for
methylation reactions by DNA- and histone-methyltransferases
(DNMTs and HMTs) (143–145); (b) Flavin adenine dinu-
cleotide (FAD), which is a cofactor for lysine specific demethy-
lase 1 (LSD1) (144, 146); (c) α-ketoglutarate, which is an elec-
tron donor and cofactor for the α-KG/Fe2+-dependent dioxyge-
nases Jumonji-C domain (JmjC) histone demethylases (HDMs)
and ten–eleven translocation (TET) proteins, respectively (143,
144); (d) Nicotinamide adenine dinucleotide (NAD), which is a
cofactor for the sirtuins family of histone deacetylases (HDACs)
and poly(ADP-ribose)polymerase (PARP) (143, 147–151); and
(e) Acetyl Coenzyme A, which is not only an important precur-
sor for the de novo biogenesis of fatty acids, but also an essential
cofactor for histone acetyl transferases (HATs) and the acetyla-
tion of non-histone proteins involved in cell metabolism (145,
152–155). Because alterations in the supply of these cofactors
may affect DNA methylation, alter chromatin structure, and
change posttranslational modifications of non-histone proteins
that influence the regulation of gene expression reprogram-
ing to stemness, and because cofactors and modifying enzymes
are always present at some level, the current challenge is to
understand how localized fluctuations in levels of metabolites
control chromatin modifiers in space and time to operate as
mechanisms of specificity that prevent all genes from being reg-
ulated synchronously. Enzyme recruitment with DNA-binding
factors, local depletion or excess cofactors, or the modification
of spatial and temporal sublocalization of enzymes within the
nucleus might likely account for a hierarchy of target chromatin
regions and associated genes (116, 156), thus translating CSC
metabotypes into CSC methylation maps.
– Beyond the more general effects on epigenetics brought about by
changes in the availability of substrates or cofactors for enzymes
that regulate chromatin structure and gene expression, muta-
tions in metabolic enzymes have been linked to the generation of
oncometabolites, which directly drives epigenetic reprograming
in cancer cells. Ever-growing in vitro and in vivo studies have
provided strong biochemical, cell biological, and genetic evi-
dence that oncometabolites can drive tumorigenesis and tumor
maintenance by regulating histone and DNA modifications and
engaging a metabolic block in cellular differentiation. This is
the case of the currently recognized oncometabolites R(-)-2-
hydroxyglutarate (2-HG), fumarate, and succinate, which accu-
mulate due to defects in the TCA cycle enzymes isocitrate dehy-
drogenases (IDHs), fumarate hydratase (FH), and succinate
dehydrogenase (SDH), respectively. Defects in these TCA cycle
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FIGURE 3 | Metabostemness: a metabolo-epitranscriptional switcher.
A highly active crosstalk between metabolism and epigenetics allows the
causal integration of metabolism and metabolites with genetic programs to
coordinately regulate CSC function and fate. Nutrient levels and cell
metabolism will significantly affect levels of the metabolites, which are
required substrates of chromatin-modifying enzymes that use them to modify
both histones and DNA (116). A minor portion of the lucose that enters the
glycolytic pathway is branched to hexosamine biosynthetic pathway to
produce GlcNAc, a substrate for histone GlcNAcylation by the OGT enzyme. It
is well known that the flux through glycolysis determines the NAD+/NADH
ratio, a crucial metabolic parameter for the activities of sirtuin histone
deacetylases. Citrate and α-ketoglutarate (α-KG) are intermediates of the TCA
cycle that can be exported out of mitochondria; cytosolic citrate is converted
to acetyl-CoA that is employed as a donor for HAT-mediated histone
acetylation. JHDM and TET use α-KG as cofactor for histone and DNA
demethylation reactions, respectively. S-adenosylmethionine (SAM), which is
synthesized from essential amino acid methionine, is a donor for DNA
methylation via HMT and DNMT. A low ATP/AMP ratio indicative of metabolic
stress can activate AMPK, which can translocate to chromatin and
phosphorylate histones. In this scenario, we propose that certain
metabotypes might operate as pivotal molecular events rendering a non-CSC
cell susceptible to epigenetic and transcriptional rewiring required for the
acquisition of aberrant stemness and, concurrently, of refractoriness not only
to apoptosis but also to differentiation. Only certain cell metabotypes would
be compatible with the operational properties exclusively owned by CSC
cellular states; conversely, certain metabotypes would impose cellular modes
protected against CSC reprograming. In other words, the molecular logic
behind the conversion of non-CSC into CSC can be better understood in
terms of cellular metabotypes that operate as pathways (“permissive”) or
roadblocks (“protected”) by facilitating or impeding, respectively, the
transcriptional events and signal transduction pathways that lastly coordinate
the intrinsic and microenvironmental paths to CSC cellular states.
enzymes caused inherited benign or malignant tumors by alter-
ing DNA and histone modifications to cause widespread tran-
scriptional dysregulation (31–45). Indeed, the identification of
cancer-associated mutations in metabolic enzymes has provided
the strongest support ever for the argument that the metabo-
lism rewiring observed in cancer plays a significant role in cancer
development. Crucially, by highlighting the similarities in the
nuclear reprograming pathways that are involved in the gener-
ation of iPSCs and of the tumor-initiating action of CSC-like
cells, it has recently been suggested that a stemness-related hall-
mark of cancers may be mutations or expression changes in
metabolic genes that are implicated in the regulation of DNA
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methylation plasticity such as IDHs (7). Lu and Thompson
(116) originally suggested that, during progenitor cell differenti-
ation, the inhibition of the HDM JHDM by the oncometabolite
2-HG,which is aberrantly synthesized by the neomorphic muta-
tions of IDH enzymes, causes defective histone demethylation
and blocks the accessibility of differentiation-related genes. The
2-HG-driven inhibition of JHDM as well as that of the TET fam-
ily of DNA demethylases, which operate as failsafe mechanisms
to protect promoters from aberrant DNA methylation, should
lead to progressive DNA hypermethylation and permanently
“lock” differentiation-related genes in a silent state; the result-
ing differentiation arrest might facilitate cancer development
through the accumulation of undifferentiated cells capable of
self-renewal. Goding et al. (7) now propose that the cell of
origin dictates the metabolo-epigenetic relationship between
reprograming and cancer. As originally proposed by Lu and
Thompson (116), gain-of-functions IDH mutations can lead
to global hypermethylation, preventing the demethylation of
genes that are implicated in differentiation, and consequently
promoting an increase in the number of stem cells that may be
targetable by oncogenic mutations in cancers with a stem cell of
origin, such as hematopoietic malignancies. For cancers with a
non-stem cell origin including liver, breast, lung, pancreatic, and
prostate cancers, in which mutations on metabolic genes are not
widespread, Goding et al. (7) propose that an intact metabolic
function of IDH would be necessary to maintain DNA methyla-
tion plasticity and a flexible epigenetic landscape, as seen during
the generation of iPSCs.
Nevertheless, as metabolic abnormalities in cancer continue to
be uncovered, it can be expected that new metabolites or metabolic
perturbations that affect chromatin structure will be identified (53,
157). Moreover, during reprograming to a CSC cellular state, a
positive feedback loop might be established between bioenergetics
reprograming and the activity of stemness transcriptional factors;
accordingly, there is a progressive resetting of metabolite levels that
parallels the progressive changes seen in global epigenetic modi-
fications and gene expression over prolonged times of induced
pluripotency maintenance. We propose that the probabilistic
description of cell states in cancer tissues can be better described
by incorporating the connections between metabolism and chro-
matin dynamics; therefore, in order to determine how metabolism
and metabolites exert influence over epigenetic and genetic repro-
graming circuits that establish and maintain CSCs’ self-renewal
and differentiation abilities, the transition between cancer cell
states should incorporate not only a set of gene expression lev-
els, but also the metabolo-epigenetic state, i.e., S(t )= [meg1(t ),
meg2(t ), meg3(t ), . . ., megN(t )] (Figure 2).
DYNAMIC PERSPECTIVE USING WADDINGTONIAN LANDSCAPES
It is well-recognized that the Waddington landscape (158), a
metaphoric representation of cell differentiation in which pluripo-
tent stem cells are positioned at the top of a hill progressively losing
differentiation potential while going downhill into different valleys
representing irreversible differentiated cellular states, allows for the
modeling of a complex network of molecular barriers governing
cell-fate transitions. The complexity of the enormous number of
possible intracellular factors that can mitigate or impede cellular
reprograming is notably reduced into an effective energy landscape
in the Waddington model, in which cell-fates are defined by stable
states, known as “attractors,” and cell transitions are represented
as flows from one energy state to another. In this quasi-potential
Waddingtonian landscape that captures the global dynamics of
high-dimensional attractor states (i.e.,distinct entities and of regu-
latory networks representing the equilibrium solutions of how the
concentrations of interacting transcripts, proteins, and other vari-
ables in a GRN evolve over time to exhibit the natural properties of
cell types), the cancer cell types within a tumor tissue are therefore
self-stabilizing states basically defined by their “energetic” mini-
mum (i.e., the commitment is defined as the progression toward
the minimum energy) and the shape of the potential cleft. While
they are robust to small perturbations, they still allow “all-or-
nothing” transitions to other attractors including those of CSCs
given sufficiently high perturbations, as they are separated by
“hills” that correspond to “unstable” states. The latter truly rep-
resent the “epigenetic barriers” originally proposed in the 1940s
to explain cell-fate determination in contraposition to the com-
monly, but erroneously, usually claimed “epigenetic landscape” in
which unique chromatin marks such as DNA methylation and his-
tone acetylation/methylation control the activity of specific genes,
thereby acting as the crucial modulators of cell-fate. Thus, accord-
ing to a bona fide Waddingtonian model based on a rather reversed
role of chromatin modification as the prima causa of lineage-
specific gene expression patterns by “upstream” controlling the
access of transcription factors to DNA target sites (i.e., the stem-
ness transcription factors themselves, endowed with sequence-
recognition capability, are in charge of initiating the opening of
chromatin at specific sites, followed by a directional cooperation
with the chromatin-modifying enzymes that they recruit to their
target loci), we argue that the metabolo-epigenetic nature of the
potential barriers between non-CSC and CSC cell states actually
determines how metabolism and metabolites exert influence over
or functionally substitute the genetic and epigenetic circuits that
establish and maintain stem cell reprograming in cancer tissues.
In this new scenario, the underlying regulatory logic that gov-
erns the interactions between genes and proteins should include
the cellular metabotype to better define the actual “metabolo-
epitranscriptional regulatory network (MGRN)” architecture of
cancer tissues.
A glossary of terms might facilitate the understanding of
the metabolo-epigenetic landscapes in cancer tissues. The term
“metabotype” refers to a cellular phenotype characterized by dif-
ferent metabolites’ levels that can be described by means of four
variability criteria: (a) the presence–absence of metabolites; (b)
the concentration levels of metabolites; (c) the relative levels or
ratios between metabolites; and (d) metabolic profiles. The term
“MGRN” comprises the epigenetic state, genes transcripts, pro-
teins, and metabolites that can interact with each other within
a cell, including the underlying regulatory logics that govern the
interactions between chromatin dynamics, transcripts, proteins,
and metabolites. The delineation of “metabolo-epitranscriptional
rate equations” refers to mathematical representations of how the
concentrations of interacting cellular methylome, gene transcripts,
proteins, and metabolites in an MGRN evolve over time in a cell. A
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“metabolo-epitranscriptional attractor” describes the equilibrium
solutions of the metabolo-epitranscriptional rate equations that
represent observable cellular states and can be visualized as wells,
or depressions, in a metabolo-epigenetic landscape. A “metabolo-
epitranscriptional basin of attraction” includes the set of initial
conditions of the metabolo-epitranscriptional rate equations that
describe how a particular cell moves to particular metabolo-
epitranscriptional attractors. It therefore represents a fate-primed
subset of a given population, i.e., a particular cellular state.
The concepts of attractors and the associated landscape pictures
provide a very useful conceptual framework in considering the
metabolo-epigenetic nature of the non-CSC and CSC substates.
Although it might be argued that the power of a dynamic perspec-
tive of cancer metabostemness using Waddingtonian metabolo-
epigenetic landscapes does not extend beyond intuition, we should
acknowledge that, in some examples, it has been possible to mathe-
matically describe the relevant attractors and to make predictions
about the paths that differentiating cells follow from the undif-
ferentiated, undetermined stem cell state, and vice versa (106,
115, 159). Moreover, the importance of pursuing mathematical
models for stemness and differentiation issues should be empha-
sized when considering that a CSC cellular state should represent a
“metabolo-epitranscriptional attractor” in which the maintenance
of stemness might not only involve an active process of main-
taining this “ground-state,” but also prevent cells from leaving it
(160). In this scenario, where CSC cellular states are expected to
have an innate program for self-replication that might not require
extrinsic instruction, which may certainly account for their latent
tumorigenicity, the development of the methods and procedures
to mathematically model MGRNs involved in determining self-
renewal and pluripotency will not only provide new insights into
switch and reprograming properties in cancer tissues, but will also
reveal specific, metabolically driven fluctuating behaviors; in par-
ticular, the delineation of minimal metabolo-epitranscriptional
requirements for cancer self-renewal can pinpoint missing meta-
bolic components and interactions from CSC functionality that
can be confirmed in the laboratory, thus generating an iterative
procedure in which the occurrence of “metabostemness factors”
and “metabolic rules of attraction” is modeled.
In a first attempt to provide a defined platform for the precise
description and dissection of the CSC state in minimal metabolo-
epitranscriptional terms, we recently developed the methods and
procedures to mathematically model the MGRNs that might be
involved in determining pluripotency and self-renewal in mam-
mary epithelial cells; similarly to previous studies, our model for-
mulation considered that the establishment of a balance between
Oct4 and Sox2 – the core regulators of pluripotency – and/or
counteracting lineage specifiers facilitate reprograming to stem-
ness (98). Our model formulation, however, introduced for the
first time ever the epigenetic regulation of the lineage-specific
genes, which is an essential element that allows the effects of meta-
bolic regulation in the nuclear reprograming process to be taken
into account (Menendez et al., unpublished observations). In par-
ticular, we added nucleosome modification by HDM as an essential
reprograming element regulated by oncometabolites such as 2-
HG. When studying the impact of 2-HG-induced reduction of
HDM activity on both the epigenetic landscape of pluripotency
and the reprograming kinetics (Figure 4), the following was
predicted:
(a) a metabolically driven small reduction of HDM activity
should be sufficient to notably lower the barriers of the epi-
genetic landscape, thus allowing differentiated cells to more
easily enter into stem cell macrostates;
(b) the reduction in average reprograming time should vary expo-
nentially with the metabolically imposed reduction of HDM
activity, suggesting that even modest metabolic decreases of
histone demethylation would produce a considerable increase
in reprograming efficiency; and
(c) the metabolic-induced reduction of HDM activity should
transfer a portion of the basin of attraction of the differen-
tiated to the pluripotent state thus increasing the size of the
basin of attraction of the macrostate occupied by stem cells.
Second, the creation of non-transformed mammary epithe-
lial cells with clinically relevant heterozygous knock-in of the
2-HG-producing IDH1 R132H mutation allowed us to generate
proof-of-concept data supporting the actual reprograming activ-
ity of oncometabolites predicted in our mathematical model. The
experimental validation of functional predictions confirmed the
following:
(a) the endogenous accumulation of oncometabolites such as
2-HG is likewise sufficient to significantly enhance and accel-
erate the efficient generation of induced CSC-like-cells when
using the four transcription factors Oct4, Sox2, Klf4, and
c-Myc;
(b) even transient exposure to oncometabolites can operate as a
microenvironment-driven dedifferentiation event that facil-
itate “pathological reprograming” because several hours of
exposure with a cell-permeable form of 2-HG can fully reca-
pitulate the promoting effects of IDH1 mutations on switch-
ing differentiated mammary epithelial cells into induced
CSC-like cells; and, more importantly
(c) 2-HG can substitute for Klf4 and c-Myc in reprograming-
factor combinations leading to the enhancement and acceler-
ation of reprograming non-CSC into induced CSC-like cells
when solely using Oct4 and Sox2.
By impacting the epigenetic remodeling that facilitates the tran-
sition between non-CSC and CSC functional states, oncometabo-
lites such as 2-HG likewise appear to operate as bona fide “meta-
bostemness reprograming factors” that determine the cancer tis-
sue proclivity of generating a given number of CSCs in a given
time. Because we employed a non-tumorigenic, non-transformed
genetic background that, upon introduction of defined repro-
graming factors, has been found to generate tumorigenic cells
with CSC properties (161), our findings demonstrating how
small-molecule components of metabolism such as 2-HG effi-
ciently drive significant enhancement and acceleration of CSC
reprograming strongly support the notion that metabostemness
factors could poise cells with chromatin states competent for
rapid dedifferentiation, creating a persistent pre-neoplastic state
suitably primed for later transcriptional alterations to finish the
reprograming of non-CSC into CSC cellular states.
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FIGURE 4 | Metabostemness: metabolic regulation of the efficient and
rapid reprograming-to-cancer stemness in cancer tissues. The cellular
metabotype can significantly alter the efficiency and speed of CSC
reprograming in cancer tissues by lowering the barriers of the epigenetic
landscape and by increasing the size of the basin of attraction of CSC cellular
states. In this scenario, even modest changes in the protected versus
permissive nature of the cellular metabotype are expected to produce a
considerable change on the kinetic efficiency of the reprograming process.
Given that metabolism represents a junction system receiv-
ing cumulative signals from upstream (genome, transcriptome,
and proteome) and downstream (microenvironment) systems,
pre-malignant, and cancer cells can adapt, resist, or react to
multi-omic effects through different types of metabolism and,
therefore, based on differential regulation, synthesis, and avail-
ability of cellular metabolites. Indeed, all the – omic characteristics
that drive cancer plasticity concurrently provide to metabolism a
flexibility that can be described by means of, at least, four vari-
ability criteria, i.e., the occurrence of certain “elite” metabolites,
their concentration levels, their relative levels or ratios between
metabolites, and metabolic profiles. The occurrence of particular
metabolites should be viewed as a qualitative criterion concern-
ing a strong metabolomic parameter specifically stimulated by
particular cancer cell states or that locks cancer cells in a given
state by merely being present (e.g., oncometabolites). Although
apparently simplistic, this binary aspect of associating unique
metabolomic parameters with radically different non-CSC versus
CSC cellular “species” is strongly supported by the abovemen-
tioned findings with the oncometabolite 2-HG. In this scenario,
metabotypes based on the presence–absence of some particular
metabolites can have high taxonomic value at specifically differ-
entiating non-CSC versus CSC cellular states in cancer tissues.
The increase in the concentration levels of some metabolites could
also operate as intrinsic factors governing the proclivity of non-
CSC-to-CSC transitions. For instance, the upregulation of the
middle glycolysis intermediate fructose-1,6-bisphosphate upon
epigenetic silencing of the gluconeogenic enzyme fructose-1,6-
biphosphatase is differentially employed by CSCs as a mechanism
of glucose flux maintenance and the lowering of reactive oxy-
gen species (ROS) via glycolysis and other associated biosynthetic
pathways (127). Forthcoming studies should elucidate whether
metabolic ratios between the concentration levels of structurally
close metabolites can also provide biochemical functional discrim-
ination between non-CSC and CSC cellular states in heteroge-
neous cancer populations. In the same regard, should CSC cellular
states possess specific changes in the capacities and kinetics of cer-
tain metabolic modes, the discovery of unique, CSC-associated
metabolic flux imprints will remain a challenge for the field (see
below).
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TISSUE-DEPENDENT CANCER METABOLIC PROGRAMS: THE
“METABOLIC MEMORY” OF REPROGRAMED CSC
A dynamic perspective of the metabostemness trait using
Waddingtonian metabolo-epitranscriptional landscapes can
explain why we are accumulating evidence that tumor cells’metab-
olism, often considered a single entity differing from normal cell
metabolism, rather exhibits a wide diversity of metabolic phe-
notypes (162). The heterogeneous expression of metabolic genes
is observed across tissue types and, therefore, the metabotypic
expression pattern appears to reflect cancer cells’ propensity to
adapt the pre-existing metabolic network to successfully support
the cancer tissue’s altered needs. Where it has been studied, the
metabotype of tumors is a function of both the genetic lesions
driving tumorigenesis and the tissue from which the cancer arose
(163). Although it has been suggested that this heterogenous meta-
bolic pattern across tissue types can reflect cancer cells’ propensity
to adapt the pre-existing metabolic network to support the neo-
plastic tissue’s altered metabolic needs (162), the metabostemness
trait can provide a radically different view of the occurrence of
tissue-dependent cancer metabolic phenotypes.
A shift in the balance between mitochondrial OXPHOS and
glycolysis that reconfigures the cellular anabolic requirements (i.e.,
high glycolytic carbon flux and the increased decoupling from ATP
production in mitochondria) precedes the appropriate acquisition
of stemness traits in iPSCs (10–30, 105). Similar to well-recognized
genetic and epigenetic factors, bioenergetics reprograming cru-
cially operates as an enabling regulator of cellular reprograming
to stemness because the self-renewal and pluripotency attributes
cannot be efficiently acquired in the presence of an inadequate
bioenergetic metabotype. Thus, the efficiency of reprograming is
higher the closer the glycolytic/OXPHOS energy metabolism pro-
files of the starting somatic cells are to the pattern observed in
ESCs. Moreover, bioenergetics resetting has an early, active role
during reprograming because manipulations that inhibit glycoly-
sis reduce, whereas augmenting glycolysis enhances reprograming
efficiency, respectively. Therefore, only when a crucial, very early
step of engagement to the stemness’ bioenergetics metabotype is
correctly initiated can transcriptional regulators of self-renewal
and pluripotency then induce additional endogenous factors to
acquire a bona fide stem cell cellular state while maintaining
the reprograming cells’ bioenergetics’ competence. Accordingly,
induced pluripotency can be achieved with a combination of only
one stemness transcription factor and small molecules able to facil-
itate the metabolic transition from mitochondrial OXPHOS to
glycolysis. Moreover, there is a progressive resetting of metabo-
lite levels that parallels the progressive changes seen in global
epigenetic modifications and gene expression with late passage
iPSCs significantly closer to the metabolo-epigenetic profiles of
ESCs (19, 164).
The abovementioned findings strongly suggest that, similar to
the “epigenetic memory,” a “metabolic memory” also exists that
can be partially retained through the reprograming process and
might significantly influence the functioning and differentiation
potential of iPSCs from cells of different tissues. Although little is
known about the bioenergetics resetting of CSCs, it appears that,
similarly to iPSCs, a direct link might exist between the occurrence
of a metabolic switch from OXPHOS to aerobic glycolysis and the
occurrence and maintenance of CSC cellular states. Compared to
their more differentiated progeny, the acquisition of a stem cell
cellular state might necessarily promote changes in the bioener-
getics metabotype because CSCs appear to preferentially perform
glycolysis over OXPHOS, at least in some cancer types. Accord-
ingly, recent studies have confirmed that breast CSCs shift from
mitochondrial OXPHOS toward fermentative glycolysis and are
sensitive to treatment with 2-deoxyglucose, a well-known inhibitor
of glycolysis (165). A direct link between glucose metabolism
and cancer stem/initiating cells has similarly been established in
glioblastoma cancer tissues (166). Once again, by following the
numerous parallels between the processes of reprograming differ-
entiated cells-to-iPSCs and differentiated cells-to-CSC, it seems
reasonable to suggest that certain bioenergetics features such as
the Warburg effect can no longer be viewed as the single metabolic
entity shared by all the cancer tissues, but rather as the archetypi-
cal aspect of the undifferentiated state owned by CSCs. As recently
pointed out by Pacini and Borziani (167), the specific metabolic
phenotype known as the Warburg effect might not be consid-
ered a metabolic signature that is acquired during the oncogenesis
process; conversely, the Warburg effect might represent an aber-
rant expression of a metabolic layout that is distinctive from the
undifferentiated state owned by CSCs. Pacini and Borziani (167)
further consider that there is a gradual and irreversible establish-
ment of an undifferentiated state, with a gradual or complete loss
of OXPHOS, rather than respiration in itself, which is often present
in neoplasms, as originally described by Otto Warburg almost a
century ago. Thus, these authors view the permanent shift toward
a Warburgian energetic and metabolic state as an essential contrib-
utory cause of cancer, as it might represent the central link between
genetic/epigenetic instability and the CSC theory considering that
a characteristic and essential feature of each neoplasm is the lack
of differentiation.
Our metabostemness proposal provides an alternative expla-
nation to the apparently contradictory fact that certain bioen-
ergetic metabotypes such as the OXPHOS-to-glycolysis bioener-
getics resetting can be commonly adopted by CSC cellular states
from different cancer tissues, whereas, the metabolic networks of
individual tumors more closely resemble those of the normal tis-
sue from which the tumor arose than other tumors that develop
in different organ sites (168). From a Waddingtonian perspec-
tive, establishing a CSC cellular state is an “uphill battle” against
the global slope in the landscape, which accounts for the arrow
of time of cancer development. Certain metabolic events (e.g.,
the Warburg effect) might lower the barriers of the epigenetic
landscape to provide “smoothly ascending slopes” while concomi-
tantly enlarging the CSC attractor basin and thus promoting the
ground-state character of the CSC cell state that is self-maintaining
(Figure 4). However, the Warburgian metabolic state of CSC
will be nevertheless globally situated at a “high altitude,” which
affords the state a strong urge to “differentiate away” and popu-
late all other cancer states attractors situated at a lower “altitude”;
upon certain perturbations the metabolo-network state will “flow
down” the valleys to the much lower attractors of differentiated
cancer cells, which, because of their “metabolic memory” will con-
vey their tissue-specific metabolic patterns without needing any
“instructive” signal.
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CANCER METABOSTEMNESS: THE CHALLENGES AHEAD
DESCRIPTION OF THE CSC-METABOLIC PHENOME: THE METABOLIC
IMPORTANCE OF THE HOST
Could we determine whether the cellular states of CSCs specifically
engage structural or functional changes in metabolic enzymes to
produce either specific or differentially enriched CSC-metabolites?
We should acknowledge that there are currently no studies on the
intracellular metabolic fluxes of CSCs. The elucidation of CSCs’
shift between OXPHOS and aerobic glycolysis based solely on
transcriptomic data would imply there are no specific changes
in CSC metabolism, as most metabolic changes are not accom-
panied by significant changes in the transcript levels of metabolic
genes. The inclusion of proteomics data would shed further light
on CSC-associated metabolism; for example, increased protein
expression throughout the glycolytic pathway could suggest that
this pathway’s activity is increased in CSC cellular states. However,
proteomics data will not be conclusive regarding changes in the
activity of certain metabolic pathways. Indeed, detailed knowledge
of cell physiology, in particular at the level of cellular metabolism,
is entirely lacking for CSCs due to the difficulty of measuring
the in vivo metabolic fluxes of mammalian cells. A better under-
standing of these fluxes will be critical in order to exploit the
metabostemness trait to eliminate tumor tissues in patients, espe-
cially when considering that the tumor cell microenvironment can
profoundly affect metabolism and influence how nutrients are
metabolized (169, 170). Moreover, tumor tissues are composed
of a heterogeneous mixture of cancer cells and normal cells, and
symbiotic metabolic relationships have been described in both
normal and malignant-tissues contexts (171–175). Because whole
body metabolic regulation can also affect tumor tissue metabo-
lism (176), incorporating the complex interplay between genetics,
microenvironment, tissue heterogeneity, and whole body metabo-
lism at the CSC-metabolic level remains an enormous challenge for
the field. In this regard, we recently reasoned that certain extracel-
lular nutrients might be the major determinant of the maintenance
and/or expansion of the metabolic states characteristic of CSC
cellular states. Using a standardized high-throughput metabolic
phenotyping platform [i.e., the Phenotype MicroArrays for Mam-
malian Cells (PMM) technology] based on a single-assay meta-
bolic profile of several hundred nutrient sources, we performed
a comprehensive evaluation of the phenotypic variations among
non-CSC and CSC-like isogenic cells as a starting point for uncov-
ering CSC cells’ microecological nutritional niches (5). Our study
revealed that the acquisition of stemness traits by breast epithelial
cells is sufficient to cell-autonomously enable the vectorial transfer
of energy-rich nutrients from the extracellular microenvironment
to energy-producing catabolic pathways in the CSC-like cells. We
presented the first evidence for the existence of a cell-autonomous
“reverse Warburg effect” where CSC reprograming appears to pre-
activate energy-producing pathways that can efficiently use bona
fide ketone bodies (e.g., β-hydroxy-butyric acid) and other high-
energy metabolites such as lactate and pyruvate from the extracel-
lular milieu to feed mitochondrial energy production, especially
upon starvation. Because cancer cells’ utilization of the high-
energy metabolites pyruvate, lactate, and ketones has been shown
to increase the transcriptional expression of gene profiles normally
associated with stemness, including genes commonly upregulated
in ESCs (177, 178), our results strongly suggest that global nutrient
utilization analyses should be viewed as crucial complements of
the metabolo-phenotypic characterization of CSC cellular states.
But how should a definitive elucidation of the metabolo-
phenomic maps in CSC be approached? Metabolic flux analysis
(fluxomics) is known to represent the physiological counterpart
of its sibling’s transcriptomics, proteomics, and metabolomics.
Fluxomics integrates in vivo measurements of metabolic fluxes
with stoichiometric network models to allow the determination
of absolute flux through large networks of the central carbon
metabolism. Thus, fluxomics, by comprising all metabolic con-
version rates in a cell, is being increasingly used in fundamental
and applied sciences to unravel metabolic infrastructures and
activities of metabolic networks and their regulation (Figure 5).
Accordingly, forthcoming studies should afford the systematic
determination of “CSC fluxomes” by directly inferring the immea-
surable in vivo central metabolic reaction rates through rigorous
mathematical modeling. By performing metabolomic flux analy-
ses using isotopic tracers and mass spectrometry (MS), it might be
possible to determine whether CSC cellular states possess highly
specific structural or functional changes in metabolic enzymes
and nodes that allow them to produce specific or differentially
enriched CSC-associated metabolites. CSC fluxomic experiments
are currently underway in our laboratory, which consist of feeding
the culture of EMT-induced CSC-like cells and isogenic parental
cells with a defined 13C-labeled substrate, and measuring, through
nuclear magnetic resonance (NMR) or MS, the isotopic enrich-
ment in intracellular metabolites. This information is expected
to be “stored” in terms of isotopomers (i.e., each of the possible
labeling states in which a particular metabolite can be found). The
resultant 13C-labeling in the intracellular metabolites is expected
to impose important constraints on how the labeled carbon sub-
strate is distributed throughout the metabolic network and, hence,
on the identity of the non-CSC- and CSC-associated metabolic
fluxes.
GERONCOGENESIS AND METABOSTEMNESS
The recently proposed “geroncogenesis” hypothesis states that
metabolic changes during aging (i.e., the normal decline in oxida-
tive metabolism and the development of a Warburgian glycolytic
metabolism in normal tissues) constitute an early and important
“hit” that pushes cells toward complete cellular transformation.
Wu et al. (179) propose that “is not simply the time taken to
accumulate genomic hits that accounts for the increased rate of
cancer with age, but the decline in metabolic homeostasis and
gene regulation that occurs normally as we age.” The authors place
the sirtuins, a family of NAD+-dependent deacetylases (180) that
have evolved as coordinators of physiological responses to nutri-
ent intake and energetic demand, as central to this aging-induced
dysregulation of mitochondrial metabolism. In the geroncogenic
scenario, aging induces a gradual reprograming of metabolism
toward a “cancer-like” state. This pre-metabolic transformation
certainly correlates well with our current proposal of metabostem-
ness, which calls for the need to broaden our current perception
on how metabolism and metabolites exert influence over the
transcriptional factors, the chromatin structure, and the epige-
netic circuits that establish and maintain the self-renewal and
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FIGURE 5 | Metabostemness: a fluxomic perspective. CSC cellular states
should include changes in the capacities (enzyme abundance) and kinetics
(enzyme activity) of certain metabolic nodes that might then generate
CSC-associated metabolites or metabolomic flux imprints. Metabolic flux
analysis (MFA) has become a standard tool to probe cellular metabolism and
elucidate in vivo metabolic fluxes, which are estimated from isotopic labeling
measurements combined with extracellular uptake and excretion rates.
Because 13C-MFA has been shown to provide an inherently more realistic
representation of in vivo cellular metabolism, the application of the isotopic
13C-MFA methodology might allow obtaining an integrated picture of the
metabolic fluxes specifically or differentially occurring in CSC cellular states.
In brief, a 13C-labeled substrate can be incorporated into the carbon backbone
of a wide range of CSC-metabolites and the CSC metabolome, either through
exchange or synthesis. The dynamic distribution of labeled carbon traversing
along CSC-metabolic pathways is expected to generate a characteristic
imprint of labeling patterns whose mass signature will be observed by MS. All
fluxes can be determined on an absolute scale because the physiological
fluxes in and out of non-CSC and CSC cells will be available under
experimental conditions. Mass isotopomers can be analyzed at different
times to follow the label incorporation immediately after incubating cells with
a labeled substrate. To translate the time-series labeling data into metabolic
fluxes, MS-related mathematical models could combine the balances of the
total metabolite pools and of individual isotopomers to obtain complete
information about the transitions of the labeled carbons within metabolites.
The model inputs will be the isotopomer 13C time-courses and some
metabolite pools determined experimentally, in addition to the consumption
or production rates of metabolites measured in cell supernatants. Because
the isotopic transient 13C-MFA methodology does not rely on uncertain
cofactor balances it allows the estimation of fluxes through both parallel and
cyclic pathways as well as through bidirectional reactions.
differentiation capacities of CSCs. Certain aging-related metabo-
typic alterations (e.g., a shift toward a predominantly glycolytic,
Warburg-like metabolism) might operate as pivotal molecular
events rendering any type of cell of origin susceptible to epige-
netic rewiring required for the acquisition of aberrant stemness
and, concurrently, of refractoriness not only to apoptosis, but
also to differentiation. From a geroncogenic perspective (179),
certain “gerometabolites” (43) can operate as bona fide meta-
bostemness reprograming factors that poise cells with chromatin
states competent for rapid dedifferentiation while concomitantly
setting the idoneous metabolic stage for later genetic alterations to
finish the reprograming of non-cancerous into tumor-initiating
cells. From a dynamic perspective using Waddingtonian land-
scapes, metabolic changes during aging could causally control
or functionally substitute the epitranscriptional orchestration of
the genetic reprograming redirecting normal and non-CSC tumor
cells toward less-differentiated CSC cellular states by accelerating
the number of “stochastic transitions” (i.e., a case in which the
metabolo-epitranscriptional rate equations occurring in a given
MGRN cannot specify how a cellular state will move from non-
CSC attractors to CSC attractors) and increasing the probability
of “deterministic transitions” (i.e., a case in which the metabolo-
epitranscriptional rate equations occurring in a given MGNR
specify how a cellular state will move from non-CSC attractors to
CSC attractors once appropriate initial conditions such as genomic
hits are defined). By impacting the epitranscriptional remodeling
that facilitates the transition between non-CSC and CSC func-
tional states, the metabostemness trait determines the cancer tissue
proclivity of generating a given number of CSCs in a given time-
frame, thus providing a functional extension of the geroncogenesis
hypothesis at the stem cell level. The gero-metabostemness sce-
nario is consistent with the strong association between cancer
prevalence and type 2 diabetes, obesity, and sedentary lifestyle
and might be counteracted by exercise, calorie restriction (CR),
and CR mimetics that may prevent aging tissues from undergo-
ing the metabolic switch in the first place. Forthcoming studies
should mechanistically evaluate how organismal diet, stem cell
function, and cancer initiation are interconnected (181) and the
implications for cancer prevention using metabolic drugs (e.g.,
biguanides) or natural dietary products including polyphenolic
xenohormetins (8, 182, 183).
METABOSTEMNESS AND THERAPEUTICS: FROM
METABO-STEMOTOXIC DRUGS TO ANTI-CSC SMART FOODS
The fact that CSC can be generated de novo from more differen-
tiated cells adds a crucial concern to the therapeutic elimination
of CSC cellular states: how can we resolve the apparently impossi-
ble problem of suppressing the molecular biology of the stemness
itself as the sole credible target against CSC? The proposed meta-
bostemness hallmark critically contributes to the gaining and
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retaining of the stem cell-like fate in pre- and malignant-tissues
because, as mentioned above, it operates as the physiological glue
that connects all the omic layers with a self-autonomous CSC-
metabolic quality, thus establishing a therapeutically targetable
metabolic continuum in the reprograming-differentiation model
of cancer genesis and progression. The metabostemness hallmark
not only dictates the plasticity of the original differentiated cell
that is targeted so as to be reprogrammable by early or late genetic
and/or epigenetic hits, but, by removing or remodeling the poten-
tial barriers between non-CSC and CSC cellular states, it can also
operate as a bona fide accelerator of the reprograming process,
allowing cells to rapidly progress toward the acquisition of a
CSC-like status. Because gains and losses of the metabostemness
trait can shift the balance of the non-CSC-to-CSC interconver-
sion in one direction or another, it then follows that only certain
cell metabotypes will be compatible with the operational proper-
ties exclusively owned by CSC cellular states; conversely, certain
metabotypes will impose cellular modes refractory to CSC repro-
graming. In other words, the molecular logic behind the conver-
sion of non-CSC into CSC can be understood in terms of cellular
metabotypes that operate as pathways or roadblocks by facilitat-
ing or impeding, respectively, the transcriptional events and signal
transduction pathways that lastly coordinate the reprograming
paths to CSC cellular states. Since metabolic (like epigenetic) pro-
grams, and unlike most genetic actors involve in stemness (e.g.,
loss-of-function mutations in tumor-suppressors, the activation
of non-catalytic transcription factors), can be erased, manipu-
lated, and reinitiated, the inclusion of the metabostemness hall-
mark as a new-dimensional cancer driver opens an entirely new
framework for cancer prevention and treatment based on CSCs’
unique metabolic dependencies. Because small perturbations in
a particular metabolic pathway or metabolite might have dras-
tic consequences on the formation, maintenance, and evolution of
CSC, an unambiguous elucidation of a putative metabo-stem con-
nection remains mandatory before we could develop a new gener-
ation of therapies directed against CSCs’ metabolic dependencies.
Accordingly, anti-metabolic reprograming strategies begin to pro-
vide a roadmap for the generation of novel “metabo-stemotoxic”
therapies that metabolically target CSCs in biologically aggres-
sive tumor types; in this regard, perhaps it is not surprising
that the potential applications for biguanides in oncology (184)
closely relate to their differential metabolic effects during the cel-
lular transformation and CSC stages (185). A growing number of
studies have demonstrated that the biguanide metformin selec-
tively ablates CSCs, as evidenced by the decreased expression of
pluripotency-associated genes, CSC-associated surface markers,
and other CSC-specific properties including tumor-initiation (83,
84, 166, 185–204).
Moreover, a definitive elucidation of the metabolo-phenomic
maps of CSC cells may reveal an unforeseen route to the devel-
opment of therapies against not only the intrinsic metabolic
energy-generating machinery of CSC cells, but also their nutri-
tional niches. The emerging discipline of nutritional genomics or
nutrigenomics includes both the study of the effects of diet on an
individual’s gene activity and health and the study of how genetic
composition affects nutrient metabolism (205–208). Through an
understanding of the unique roles of specific nutrients and their
possible roles in boosting CSC-like cell phenotypes, it might
be possible to customize “smart foods” or systemic “metabolic
nichotherapies” tailored to the specific nutritional phenomes pos-
sessed by cells with CSC cellular states. Nevertheless, because
new techniques such as multi-isotope imaging mass spectrometry
(MIMS) permit the high-resolution tracking of heavy isotope-
labeled molecules upon utilization by specific types of cells (209,
210), the unique metabolic fluxes generated by the catabolic
energy-producing machinery of CSC could be implemented in
a novel manner to monitor the spatio-temporal distributions and
functionality of CSC cellular states in real-time.
COROLLARY
In view of recent groundbreaking studies showing that aging-
related decline of certain metabolites can set the metabolic stage
for later mutations to drive tumorigenesis (i.e., the geroncogenesis
hypothesis) and that the epigenetic fate determination of differen-
tiated cells might be converted to pluripotency by microenviron-
mental cues, it is time to paradigmatically rethink our perception
of the regulatory role of metabolic reprograming in cancer cell-fate
decisions. Frustrated by the gene-centric guidelines that usually
govern of conventional approaches against CSC, we recently envi-
sioned that the incorporation of robust metabolic phenomics, i.e.,
the systematic acquisition and objective documentation of cancer
metabolic data at the level of CSC cellular states, might revolution-
ize the advancement of CSC-related cancer precision medicine.
Our current proposal of the metabostemness cancer hallmark
should forge a new and different path to treating and monitor-
ing cancer through the metabolic phenome of CSC cellular states.
Under the assumption that the molecular biology of the stemness
transformation itself would be the sole credible target in CSC, a
systematic combination of biology, biochemistry, pharmacology,
genetics, fluxomics, and mathematical approaches should unam-
biguously provide the first qualitative and quantitative phenomic
representation of the metabolic state of CSC, thus unlocking an
almost unexplored field of discovery in cancer research. By gener-
ating a robust product engine to interrogate the differential cellular
metabolism of CSCs relative to normal and non-CSC tumor cells,
we might discover an unforeseen new phenomic hallmark of
cancer that we have called cancer metabostemness.
Previously, scientists believed that metabolic changes were a
mere consequence of aberrant cancer cell growth. We propose
that metabolic reprograming of CSC has cancer-causing activ-
ity. This proposal suggests an alternative explanation and offers
the possibility of delineating a metabolic roadmap for the acqui-
sition and maintenance of CSC cellular states that might not
even require pre-existing mutations or rearrangements of well-
established “cancer genes.” Moreover, identifying the metabotypic
infrastructure of CSCs will add a novel dynamic,phenomic dimen-
sion to well-recognized cancer hallmarks. Should CSC possess
specific changes in the capacities and kinetics of certain meta-
bolic nodes, the unique metabolic flux imprints generated by
CSC could be revolutionarily implemented to monitor CSCs’
spatio-temporal distribution and functionality in real-time. Once
in the clinic, this approach can be used to pursue unique and
potentially more rapid clinical development pathways by ther-
anostically focusing on cancer populations defined by specific
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FIGURE 6 | Metabostemness: a therasnostic perspective. A qualitative
and quantitative representation of the CSC-metabolic state will add a novel
dynamic dimension to other well-known cancer hallmarks. Such a
description of the CSC-metabolic phenome would make it possible to
metabolically create non-permissive (or “hostile”) metabotypes to prevent
the occurrence of cellular states with tumor- and metastasis-initiating
capacities. In the clinic, the cancer metabostemness attribute will be the
basis to rapidly pursue unique therapeutic approaches that target the
addiction of CSCs to certain metabolic infrastructures and metabolic fluxes
at the cell-intrinsic, microenvironmental, and/or systemic levels.
Importantly, the opportunities and challenges for targeting the metabolic
infrastructure of CSCs might be rapidly achieved because existing
metabolic drugs may be easily repositioned from pre-clinical stages to
clinical approaches. For instance, the drugs that would arise from the
knowledge-based drug repositioning strategies selected to metabolically
suppress the functionality of CSCs could silently operate as “cancer tissue
sweepers” of cells capable of initiating and propagating tumors while
sparing their normal counterparts. Moreover, differentiating between the
specific characteristics of normal tissue SCs and CSCs may be an
essential requisite for assessing the best treatment targets for CSCs while
minimizing sequelae. The specific, efficient elimination of the malignant
teratocarcinoma-initiating cells using the metabolic drug metformin (198)
strongly supports the suggestion that the phenomic metabostemness
hallmark is a previously unrecognized, indispensable component of the
CSC machinery. In addition, the phenomic metabostemness hallmark will
allow an “all-in-one” therasnostic approach in cancer diseases, an
emerging tool in drug discovery and commercialization that might allow us
to take pharmacometabolomics-based precision medicine from the lab to
the “point-of-care,” the patient. Should CSC possess specific changes in
the capacities and kinetics of certain metabolic nodes, the unique
metabolic flux imprints generated by CSC could be revolutionarily
implemented to monitor the spatio-temporal distribution and functionality
of CSCs in real-time. Coupling metabostemness-based drug testing with
the use of non-invasive devices (e.g., MIMS, NMR/MRS, and circulating
metabolomics) that can accurately monitor in real-time the spatio-temporal
distribution and functionality of CSC could be rapidly implemented to help
surgeons, radio-oncologists, and oncologists accelerate and improve
metabostemness-based drug discovery and development (note: the
illustrations accompanying the figure were created by “Formas
Naturales”: http://www.formasnaturales.com/).
CSC-metabolites or CSC-metabolic imprints. Indeed, we will
be able to pharmacologically establish cell metabotypes that are
protected against the reprograming events leading to CSC cellu-
lar states, thus providing the molecular bases to accelerate and
diversify our current therapeutic capacity in new clinical trials
designed to metabolically prevent and target CSC cellular states.
The metabostemness cancer hallmark generates a shifting oncol-
ogy theory that should guide a new era of metabolo-epigenetic
cancer precision medicine. The tremendous health and social
impacts of this paradigmatic shift in the origins of CSC-driven
cancer heterogeneity are suited to becoming the platform for
new biopharmaceutical strategies based on CSC-metabolic phe-
nomics and dedicated to the research and development of the
almost unexplored field of CSC-metabolic theranostics (CSC-
metabolic diagnosis+CSC-metabolic treatment; Figure 6) in
cancer diseases.
ACKNOWLEDGMENTS
This work was financially supported by the Ministerio de Cien-
cia e Innovación (SAF2012-38914), Plan Nacional de I+D+I,
MICINN, Spain.
REFERENCES
1. Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science
(2013) 339:1567–70. doi:10.1126/science.1230184
2. Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs
E, et al. The Warburg effect version 2.0: metabolic reprogramming of cancer
stem cells. Cell Cycle (2013) 12:1166–79. doi:10.4161/cc.24479
3. Menendez JA, Alarcón T, Corominas-Faja B, Cuyàs E, López-Bonet E, Mar-
tin AG, et al. Xenopatients 2.0: reprogramming the epigenetic landscapes of
patient-derived cancer genomes. Cell Cycle (2014) 13:358–70. doi:10.4161/cc.
27770
4. Campos-Sánchez E, Cobaleda C. Tumoral reprogramming: plasticity takes a
walk on the wild side. Biochim Biophys Acta (2014). doi:10.1016/j.bbagrm.
2014.07.003
5. Cuyàs E, Corominas-Faja B, Menendez JA. The nutritional phenome of EMT-
induced cancer stem-like cells. Oncotarget (2014) 5:3970–82.
6. Friedmann-Morvinski D, Verma IM. Dedifferentiation and reprogramming:
origins of cancer stem cells. EMBO Rep (2014) 15:244–53. doi:10.1002/embr.
201338254
7. Goding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat
Rev Cancer (2014) 14:568–73. doi:10.1038/nrc3781
8. Menendez JA, Joven J. Energy metabolism and metabolic sensors in stem cells:
the metabostem crossroads of aging and cancer. Adv Exp Med Biol (2014)
824:117–40. doi:10.1007/978-3-319-07320-0_10
9. Vicente-Dueñas C, Hauer J, Ruiz-Roca L, Ingenhag D, Rodríguez-Meira A,
Auer F, et al. Tumoral stem cell reprogramming as a driver of cancer: theory,

























































Menendez and Alarcón Cancer metabostemness
biological models, implications in cancer therapy. Semin Cancer Biol (2014).
doi:10.1016/j.semcancer.2014.02.001
10. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mito-
chondrial/oxidative stress pathway is repressed in human induced pluripotent
stem cells. Stem Cells (2010) 28(4):721–33. doi:10.1002/stem.404
11. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, et al. Rapamycin and other
longevity-promoting compounds enhance the generation of mouse induced
pluripotent stem cells. Aging Cell (2011) 10:908–11. doi:10.1111/j.1474-9726.
2011.00722.x
12. Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP,
et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent
glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 14:264–71.
doi:10.1016/j.cmet.2011.06.011
13. Folmes CD, Nelson TJ, Terzic A. Energy metabolism in nuclear reprogramming.
Biomark Med (2011) 5:715–29. doi:10.2217/bmm.11.87
14. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables
stemness programs. Ann N Y Acad Sci (2012) 1254:82–9. doi:10.1111/j.1749-
6632.2012.06487.x
15. Folmes CD, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell
homeostasis and differentiation. Cell Stem Cell (2012) 11:596–606. doi:10.
1016/j.stem.2012.10.002
16. Folmes CD, Arrell DK, Zlatkovic-Lindor J, Martinez-Fernandez A, Perez-Terzic
C, Nelson TJ, et al. Metabolome and metaboproteome remodeling in nuclear
reprogramming. Cell Cycle (2013) 12:2355–65. doi:10.4161/cc.25509
17. Menendez JA,Vellon L, Oliveras-Ferraros C, Cufí S,Vazquez-Martin A. mTOR-
regulated senescence and autophagy during reprogramming of somatic cells
to pluripotency: a roadmap from energy metabolism to stem cell renewal and
aging. Cell Cycle (2011) 10:3658–77. doi:10.4161/cc.10.21.18128
18. Mahmoudi S, Brunet A. Aging and reprogramming: a two-way street. Curr
Opin Cell Biol (2012) 24:744–56. doi:10.1016/j.ceb.2012.10.004
19. Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, et al. The
metabolome of induced pluripotent stem cells reveals metabolic changes occur-
ring in somatic cell reprogramming. Cell Res (2012) 22:168–77. doi:10.1038/
cr.2011.177
20. Rafalski VA, Mancini E, Brunet A. Energy metabolism and energy-sensing
pathways in mammalian embryonic and adult stem cell fate. J Cell Sci (2012)
125:5597–608. doi:10.1242/jcs.114827
21. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon
L, Menendez JA. Mitochondrial fusion by pharmacological manipulation
impedes somatic cell reprogramming to pluripotency: new insight into the
role of mitophagy in cell stemness. Aging (Albany NY) (2012) 4:393–401.
22. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-
Ferraros C, et al. Activation of AMP-activated protein kinase (AMPK) provides
a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle
(2012) 11:974–89. doi:10.4161/cc.11.5.19450
23. Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C,
Menendez OJ, et al. The mitochondrial H(+)-ATP synthase and the lipogenic
switch: new core components of metabolic reprogramming in induced pluripo-
tent stem (iPS) cells. Cell Cycle (2013) 12:207–18. doi:10.4161/cc.23352
24. Corominas-Faja B, Cufí S, Oliveras-Ferraros C, Cuyàs E, López-Bonet E,
Lupu R, et al. Nuclear reprogramming of luminal-like breast cancer cells gen-
erates Sox2-overexpressing cancer stem-like cellular states harboring tran-
scriptional activation of the mTOR pathway. Cell Cycle (2013) 12:3109–24.
doi:10.4161/cc.26173
25. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F, et al. Autophagy
in stem cells. Autophagy (2013) 9:830–49. doi:10.4161/auto.24132
26. Wang S, Xia P, Ye B, Huang G, Liu J, Fan Z. Transient activation of autophagy
via Sox2-mediated suppression of mTOR is an important early step in repro-
gramming to pluripotency. Cell Stem Cell (2013) 13:617–25. doi:10.1016/j.
stem.2013.10.005
27. Xu X, Duan S, Yi F, Ocampo A, Liu GH, Izpisua Belmonte JC. Mitochon-
drial regulation in pluripotent stem cells. Cell Metab (2013) 18:325–32.
doi:10.1016/j.cmet.2013.06.005
28. Bukowiecki R, Adjaye J, Prigione A. Mitochondrial function in pluripo-
tent stem cells and cellular reprogramming. Gerontology (2014) 60:174–82.
doi:10.1159/000355050
29. Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing
stem cells. Nat Rev Mol Cell Biol (2014) 15:243–56. doi:10.1038/nrm3772
30. Perales-Clemente E, Folmes CD, Terzic A. Metabolic regulation of redox status
in stem cells. Antioxid Redox Signal (2014). doi:10.1089/ars.2014.6000
31. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA,
et al. The common feature of leukemia-associated IDH1 and IDH2
mutations is a neomorphic enzyme activity converting alpha-ketoglutarate
to 2-hydroxyglutarate. Cancer Cell (2010) 17:225–34. doi:10.1016/j.ccr.2010.
01.020
32. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite
2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent
dioxygenases. Cancer Cell (2011) 19:17–30. doi:10.1016/j.ccr.2010.12.014
33. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al.
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
EMBO Rep (2011) 12:463–9. doi:10.1038/embor.2011.43
34. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in
cancer. J Mol Med (Berl) (2011) 89:213–20. doi:10.1007/s00109-011-0728-4
35. Yang M, Soga T, Pollard PJ, Adam J. The emerging role of fumarate as an
oncometabolite. Front Oncol (2012) 2:85. doi:10.3389/fonc.2012.00085
36. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with
cancer. J Clin Invest (2013) 123:3652–8. doi:10.1172/JCI67228
37. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mech-
anisms, models, and clinical opportunities. Cancer Discov (2013) 3:730–41.
doi:10.1158/2159-8290.CD-13-0083
38. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C. IDH muta-
tions in tumorigenesis and their potential role as novel therapeutic targets.
Future Oncol (2013) 9:1923–35. doi:10.2217/fon.13.143
39. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudar-
shan S, et al. The proto-oncometabolite fumarate binds glutathione to amplify
ROS-dependent signaling. Mol Cell (2013) 51:236–48. doi:10.1016/j.molcel.
2013.05.003
40. Adam J, Yang M, Soga T, Pollard PJ. Rare insights into cancer biology. Oncogene
(2014) 33:2547–56. doi:10.1038/onc.2013.222
41. Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, et al.
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate bio-
marker in patients with isocitrate dehydrogenase-mutant intrahepatic cholan-
giocarcinoma. Clin Cancer Res (2014) 20:1884–90. doi:10.1158/1078-0432.
CCR-13-2649
42. Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer
Metab (2014) 2:10. doi:10.1186/2049-3002-2-10
43. Menendez JA, Alarcón T, Joven J. Gerometabolites: the pseudohypoxic aging
side of cancer oncometabolites. Cell Cycle (2014) 13:699–709. doi:10.4161/cc.
28079
44. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al.
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote
biliary cancer. Nature (2014) 513(7516):110–4. doi:10.1038/nature13441
45. Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, et al. MYC-
driven accumulation of 2-hydroxyglutarate is associated with breast cancer
prognosis. J Clin Invest (2014) 124:398–412. doi:10.1172/JCI71180
46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell
(2011) 144:646–74. doi:10.1016/j.cell.2011.02.013
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57–70.
doi:10.1016/S0092-8674(00)81683-9
48. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Can-
cer Cell (2008) 13:472–82. doi:10.1016/j.ccr.2008.05.005
49. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in
cancer pathogenesis. Nat Rev Cancer (2007) 7:763–77. doi:10.1038/nrc2222
50. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of can-
cer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab
(2008) 7:11–20. doi:10.1016/j.cmet.2007.10.002
51. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for
cancer growth. Genes Dev (2009) 23:537–48. doi:10.1101/gad.1756509
52. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the War-
burg effect: the metabolic requirements of cell proliferation. Science (2009)
324:1029–33. doi:10.1126/science.1160809
53. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full
circle. Nat Rev Cancer (2013) 13:572–83. doi:10.1038/nrc3557
54. Hernandez-Vargas H, Sincic N, Ouzounova M, Herceg Z. Epigenetic sig-
natures in stem cells and cancer stem cells. Epigenomics (2009) 1:261–80.
doi:10.2217/epi.09.19

























































Menendez and Alarcón Cancer metabostemness
55. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic
stem cell markers expression in cancers. Biochem Biophys Res Commun (2009)
383:157–62. doi:10.1016/j.bbrc.2009.02.156
56. Maenhaut C, Dumont JE, Roger PP, van Staveren WC. Cancer stem cells: a real-
ity, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis (2010)
31:149–58. doi:10.1093/carcin/bgp259
57. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells
in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem
cells: distinct, overlapping or same populations. Oncogene (2011) 30:4609–21.
doi:10.1038/onc.2011.184
58. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all cancer
cells, all the time? Trends Mol Med (2012) 18:509–15. doi:10.1016/j.molmed.
2012.06.005
59. Ben-Porath I, Thomson MW, CareyVJ, Ge R, Bell GW, Regev A, et al. An embry-
onic stem cell-like gene expression signature in poorly differentiated aggressive
human tumors. Nat Genet (2008) 40:499–507. doi:10.1038/ng.127
60. Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F, et al. Expres-
sion of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.
BMC Cancer (2011) 11:42. doi:10.1186/1471-2407-11-42
61. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of
stem cell gene Oct-4 expression in breast cancer.Ann Surg (2011) 253:1165–71.
doi:10.1097/SLA.0b013e318214c54e
62. Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, et al. Co-expression of Oct-
4 and Nestin in human breast cancers. Mol Biol Rep (2012) 39:5875–81.
doi:10.1007/s11033-011-1398-6
63. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elor-
riaga K, et al. Sox2 expression in breast tumours and activation in breast cancer
stem cells. Oncogene (2012) 31:1354–65. doi:10.1038/onc.2011.338
64. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify
a sub-population of stem cell-like cells in ovarian cancer. Oncogene (2010)
29:2153–9. doi:10.1038/onc.2009.500
65. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, et al. Double-negative feed-
back loop between reprogramming factor LIN28 and microRNA let-7 regu-
lates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res (2010)
70:9463–72. doi:10.1158/0008-5472.CAN-10-2388
66. Zhong X, Li N, Liang S, Huang Q, Coukos G, Zhang L. Identification of
microRNAs regulating reprogramming factor LIN28 in embryonic stem cells
and cancer cells. J Biol Chem (2010) 285:41961–71. doi:10.1074/jbc.M110.
169607
67. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, et al.
Generation of tumor-initiating cells by exogenous delivery of OCT4 transcrip-
tion factor. Breast Cancer Res (2011) 13:R94. doi:10.1186/bcr3019
68. Hassiotou F, Hepworth AR, Beltran AS, Mathews MM, Stuebe AM, Hart-
mann PE, et al. Expression of the pluripotency transcription factor OCT4
in the normal and aberrant mammary gland. Front Oncol (2013) 3:79.
doi:10.3389/fonc.2013.00079
69. Madison BB, Liu Q, Zhong X, Hahn CM, Lin N, Emmett MJ, et al. LIN28B pro-
motes growth and tumorigenesis of the intestinal epithelium via Let-7. Genes
Dev (2013) 27:2233–45. doi:10.1101/gad.224659.113
70. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al.
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-
cell carcinoma. Nature (2014) 511:246–50. doi:10.1038/nature13305
71. Tam WL, Ng HH. Sox2: masterminding the root of cancer. Cancer Cell (2014)
26:3–5. doi:10.1016/j.ccr.2014.06.024
72. Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, et al. Qui-
escent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog
subgroup medulloblastoma. Cancer Cell (2014) 26:33–47. doi:10.1016/j.ccr.
2014.05.005
73. Bond JA, Oddweig Ness G, Rowson J, Ivan M, White D, Wynford-Thomas
D. Spontaneous de-differentiation correlates with extended lifespan in trans-
formed thyroid epithelial cells: an epigenetic mechanism of tumour progres-
sion? Int J Cancer (1996) 67:563–72. doi:10.1002/(SICI)1097-0215(19960807)
67:4<563::AID-IJC16>3.0.CO;2-8
74. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy
that originates from a primitive hematopoietic cell. Nat Med (1997) 3:730–7.
doi:10.1038/nm0797-730
75. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer
stem cells. Nature (2001) 414:105–11. doi:10.1038/35102167
76. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospec-
tive identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A
(2003) 100:3983–8. doi:10.1073/pnas.0530291100
77. Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma
cells. Cancer Res (1964) 24:1544–51.
78. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue
renewal: prospects for therapy by directing differentiation. Cancer Res (1988)
48:1996–2004.
79. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic
hematopoiesis: are leukemias a stem cell disorder or a reacquisition of
stem cell characteristics? Proc Natl Acad Sci U S A (2003) 100:11842–9.
doi:10.1073/pnas.2034201100
80. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell
(2008) 133:704–15. doi:10.1016/j.cell.2008.03.027
81. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer:
cancer stem cells versus clonal evolution. Cell (2009) 138:822–9. doi:10.1016/
j.cell.2009.08.017
82. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB,
Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.
Cell (2009) 139:693–706. doi:10.1016/j.cell.2009.10.014
83. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast
cancer stem cells and their dynamic equilibrium with non-stem cancer
cells via IL6 secretion. Proc Natl Acad Sci U S A (2011) 108:1397–402.
doi:10.1073/pnas.1018898108
84. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemother-
apy for prolonging tumor remission in mouse xenografts involving multi-
ple cancer cell types. Cancer Res (2011) 71:3196–201. doi:10.1158/0008-5472.
CAN-10-3471
85. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Sto-
chastic state transitions give rise to phenotypic equilibrium in populations of
cancer cells. Cell (2011) 146:633–44. doi:10.1016/j.cell.2011.07.026
86. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO,
et al. Normal and neoplastic nonstem cells can spontaneously convert to a
stem-like state. Proc Natl Acad Sci U S A (2011) 108:7950–5. doi:10.1073/pnas.
1102454108
87. Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory
circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S
A (2012) 109:14470–5. doi:10.1073/pnas.1212811109
88. Spike BT, Wahl GM. p53, stem cells, and reprogramming: tumor suppression
beyond guarding the genome. Genes Cancer (2011) 2:404–19. doi:10.1177/
1947601911410224
89. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity,
and uncertainty. Cancer Cell (2012) 21:283–96. doi:10.1016/j.ccr.2012.03.003
90. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity.
Nature (2013) 501:328–37. doi:10.1038/nature12624
91. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM,
et al. Phenotypic heterogeneity among tumorigenic melanoma cells from
patients that is reversible and not hierarchically organized. Cancer Cell (2010)
18:510–23. doi:10.1016/j.ccr.2010.10.012
92. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growth-
inhibitory and tumor-suppressive functions of p53 depend on its repression of
CD44 expression. Cell (2008) 134:62–73. doi:10.1016/j.cell.2008.06.006
93. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar
BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen
receptor-negative breast cancer. Cancer Res (2010) 70:4624–33. doi:10.1158/
0008-5472.CAN-09-3619
94. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA
miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing
CD44. Nat Med (2011) 17:211–5. doi:10.1038/nm.2284
95. Sharma SV,Lee DY,Li B,Quinlan MP,Takahashi F,Maheswaran S. A chromatin-
mediated reversible drug-tolerant state in cancer cell subpopulations. Cell
(2010) 141:69–80. doi:10.1016/j.cell.2010.02.027
96. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al.
Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc
Natl Acad Sci U S A (2011) 108:4274–80. doi:10.1073/pnas.1016030108
97. Norton L. Cancer stem cells, EMT, and seeding: a rose is a rose is a rose?
Oncology (Williston Park) (2011) 25:30–2.

























































Menendez and Alarcón Cancer metabostemness
98. Shu J, Wu C, Wu Y, Li Z, Shao S, Zhao W, et al. Induction of pluripo-
tency in mouse somatic cells with lineage specifiers. Cell (2013) 153:963–75.
doi:10.1016/j.cell.2013.05.001
99. Yamanaka S. Elite and stochastic models for induced pluripotent stem cell
generation. Nature (2009) 460:49–52. doi:10.1038/nature08180
100. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, et al. Direct
cell reprogramming is a stochastic process amenable to acceleration. Nature
(2009) 462:595–601. doi:10.1038/nature08592
101. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts,
hypotheses, unresolved issues. Cell (2010) 143:508–25. doi:10.1016/j.cell.2010.
10.008
102. Zhang Y, Li W, Laurent T, Ding S. Small molecules, big roles – the chemi-
cal manipulation of stem cell fate and somatic cell reprogramming. J Cell Sci
(2012) 125:5609–20. doi:10.1242/jcs.096032
103. Li W, Li K, Wei W, Ding S. Chemical approaches to stem cell biology and
therapeutics. Cell Stem Cell (2013) 13:270–83. doi:10.1016/j.stem.2013.08.002
104. Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S, et al. Determin-
istic direct reprogramming of somatic cells to pluripotency. Nature (2013)
502:65–70. doi:10.1038/nature12587
105. Prigione A, Adjaye J. Modulation of mitochondrial biogenesis and bioenergetic
metabolism upon in vitro and in vivo differentiation of human ES and iPS cells.
Int J Dev Biol (2010) 54:1729–41. doi:10.1387/ijdb.103198ap
106. Enver T, Pera M, Peterson C, Andrews PW. Stem cell states, fates, and the rules
of attraction. Cell Stem Cell (2009) 4:387–97. doi:10.1016/j.stem.2009.04.011
107. Huang S. Reprogramming cell fates: reconciling rarity with robustness. Bioes-
says (2009) 31:546–60. doi:10.1002/bies.200800189
108. MacArthur BD, Ma’ayan A, Lemischka IR. Systems biology of stem cell
fate and cellular reprogramming. Nat Rev Mol Cell Biol (2009) 10:672–81.
doi:10.1038/nrm2766
109. Visvader JE. Cells of origin in cancer. Nature (2011) 469:314–22. doi:10.1038/
nature09781
110. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving com-
plexities. Cell Stem Cell (2012) 10:717–28. doi:10.1016/j.stem.2012.05.007
111. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer
stem-cell model: clinical challenges and opportunities. Lancet Oncol (2012)
13:e83–9. doi:10.1016/S1470-2045(11)70257-1
112. Fessler E, Dijkgraaf FE, De Sousa E, Melo F, Medema JP. Cancer stem cell
dynamics in tumor progression and metastasis: is the microenvironment to
blame? Cancer Lett (2013) 341:97–104. doi:10.1016/j.canlet.2012.10.015
113. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol (2013)
15:338–44. doi:10.1038/ncb2717
114. MacArthur BD, Lemischka IR. Statistical mechanics of pluripotency. Cell
(2013) 154:484–9. doi:10.1016/j.cell.2013.07.024
115. Morris R, Sancho-Martinez I, Sharpee TO, Izpisua Belmonte JC. Mathematical
approaches to modeling development and reprogramming. Proc Natl Acad Sci
U S A (2014) 111:5076–82. doi:10.1073/pnas.1317150111
116. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab (2012)
16:9–17. doi:10.1016/j.cmet.2012.06.001
117. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even
Warburg did not anticipate. Cancer Cell (2012) 21:297–308. doi:10.1016/j.ccr.
2012.02.014
118. Zhang J, Nuebel E, Daley GQ, Koehler CM, Teitell MA. Metabolic regulation in
pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell
(2012) 11:589–95. doi:10.1016/j.stem.2012.10.005
119. Varlakhanova NV, Knoepfler PS. Acting locally and globally: Myc’s ever-
expanding roles on chromatin. Cancer Res (2009) 69:7487–90. doi:10.1158/
0008-5472.CAN-08-4832
120. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and ther-
apeutic opportunities. Clin Cancer Res (2009) 15:6479–83. doi:10.1158/1078-
0432.CCR-09-0889
121. Dang CV. Rethinking the Warburg effect with Myc micromanaging gluta-
mine metabolism.CancerRes (2010) 70:859–62. doi:10.1158/0008-5472.CAN-
09-3556
122. Wahlström T, Arsenian Henriksson M. Impact of MYC in regulation of tumor
cell metabolism. Biochim Biophys Acta (2014). doi:10.1016/j.bbagrm.2014.07.
004
123. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer. Evidence
that demethylation events play a role in activating type II hexokinase gene
expression. J Biol Chem (2003) 278:15333–40. doi:10.1074/jbc.M300608200
124. Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, et al. effect revisited: an
epigenetic link between glycolysis and gastric carcinogenesis. Oncogene (2010)
29:442–50. doi:10.1038/onc.2009.332
125. Wolf A, Agnihotri S, Munoz D, Guha A. Developmental profile and
regulation of the glycolytic enzyme hexokinase 2 in normal brain and
glioblastoma multiforme. Neurobiol Dis (2011) 44:84–91. doi:10.1016/j.nbd.
2011.06.007
126. Chen M, Zhang J, Li N, Qian Z, Zhu M, Li Q, et al. Promoter hyperme-
thylation mediated downregulation of FBP1 in human hepatocellular carci-
noma and colon cancer. PLoS One (2011) 6:e25564. doi:10.1371/journal.pone.
0025564
127. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by
Snail-mediated repression provides metabolic advantages in basal-like breast
cancer. Cancer Cell (2013) 23:316–31. doi:10.1016/j.ccr.2013.01.022
128. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, et al. Metabolic regulation of
cancer cell side population by glucose through activation of the Akt pathway.
Cell Death Differ (2014) 21:124–35. doi:10.1038/cdd.2013.131
129. Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A,
Leal L, et al. A DERL3-associated defect in the degradation of SLC2A1
mediates the Warburg effect. Nat Commun (2014) 5:3608. doi:10.1038/
ncomms4608
130. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Sup-
pression of induced pluripotent stem cell generation by the p53-p21 pathway.
Nature (2009) 460:1132–5. doi:10.1038/nature08235
131. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking
the p53 tumour suppressor pathway to somatic cell reprogramming. Nature
(2009) 460:1140–4. doi:10.1038/nature08311
132. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al.
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009)
460:1136–9. doi:10.1038/nature08290
133. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated
DNA damage response limits reprogramming to ensure iPS cell genomic
integrity. Nature (2009) 460:1149–53. doi:10.1038/nature08287
134. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W,Walsh RM, et al. Immor-
talization eliminates a roadblock during cellular reprogramming into iPS cells.
Nature (2009) 460:1145–8. doi:10.1038/nature08285
135. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, et al. Mutant p53
facilitates somatic cell reprogramming and augments the malignant poten-
tial of reprogrammed cells. J Exp Med (2010) 207:2127–40. doi:10.1084/jem.
20100797
136. Tapia N, Schöler HR. p53 connects tumorigenesis and reprogramming to
pluripotency. J Exp Med (2010) 207:2045–8. doi:10.1084/jem.20101866
137. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al.
TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006)
126:107–20. doi:10.1016/j.cell.2006.05.036
138. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism
through an IKK-NF-kappaB pathway and inhibits cell transformation.Nat Cell
Biol (2008) 10:611–8. doi:10.1038/ncb1724
139. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med (Berl)
(2011) 89:237–45. doi:10.1007/s00109-011-0735-5
140. Sen N, Satija YK, Das S. PGC-1α, a key modulator of p53, promotes cell survival
upon metabolic stress. Mol Cell (2011) 44:621–34. doi:10.1016/j.molcel.2011.
08.044
141. Sen N, Satija YK, Das S. p53 and metabolism: old player in a new game. Tran-
scription (2012) 3:119–23. doi:10.4161/trns.20094
142. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic reg-
ulation by p53 family members. Cell Metab (2013) 18:617–33. doi:10.1016/j.
cmet.2013.06.019
143. Hitchler MJ, Domann FE. Metabolic defects provide a spark for the epige-
netic switch in cancer. Free Radic Biol Med (2009) 47:115–27. doi:10.1016/j.
freeradbiomed.2009.04.010
144. Teperino R, Schoonjans K,Auwerx J. Histone methyl transferases and demethy-
lases; can they link metabolism and transcription? Cell Metab (2010) 12:321–7.
doi:10.1016/j.cmet.2010.09.004
145. Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochon-
drion (2010) 10:12–31. doi:10.1016/j.mito.2009.09.006
146. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et al. p53
is regulated by the lysine demethylase LSD1. Nature (2007) 449(7158):105–8.
doi:10.1038/nature06092

























































Menendez and Alarcón Cancer metabostemness
147. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtu-
ins. Annu Rev Biochem (2006) 75:435–65. doi:10.1146/annurev.biochem.74.
082803.133500
148. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel
functions for an old molecule. Nat Rev Mol Cell Biol (2006) 7:517–28.
doi:10.1038/nrm1963
149. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease.
Trends Biochem Sci (2007) 32:12–9. doi:10.1016/j.tibs.2006.11.006
150. Quénet D, El Ramy R, Schreiber V, Dantzer F. The role of poly(ADP-
ribosyl)ation in epigenetic events. Int J Biochem Cell Biol (2009) 41:60–5.
doi:10.1016/j.biocel.2008.07.023
151. Li X, Kazgan N. Mammalian sirtuins and energy metabolism. Int J Biol Sci
(2011) 7:575–87. doi:10.7150/ijbs.7.575
152. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional
diversity of lysine acetylation revealed by a proteomics survey. Mol Cell (2006)
23:607–18. doi:10.1016/j.molcel.2006.06.026
153. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson
CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science
(2009) 324:1076–80. doi:10.1126/science.1164097
154. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cel-
lular metabolism by protein lysine acetylation. Science (2010) 327:1000–4.
doi:10.1126/science.1179689
155. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al.
Lysine acetylation targets protein complexes and co-regulates major cellular
functions. Science (2009) 325:834–40. doi:10.1126/science.1175371
156. Katada S, Imhof A, Sassone-Corsi P. Connecting threads: epigenetics and
metabolism. Cell (2012) 148:24–8. doi:10.1016/j.cell.2012.01.001
157. Johnson C, Warmoes MO, Shen X, Locasale JW. Epigenetics and cancer metab-
olism. Cancer Lett (2013). doi:10.1016/j.canlet.2013.09.043
158. Waddington CH. The Strategy of the Genes: A Discussion of Some Aspects of
Theoretical Biology. London: Allen & Unwin (1957).
159. Armond JW, Saha K, Rana AA, Oates CJ, Jaenisch R, Nicodemi M, et al. A
stochastic model dissects cell states in biological transition processes. Sci Rep
(2014) 4:3692. doi:10.1038/srep03692
160. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The
ground state of embryonic stem cell self-renewal. Nature (2008) 453:519–23.
doi:10.1038/nature06968
161. Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, et al. Induction of
cells with cancer stem cell properties from nontumorigenic human mammary
epithelial cells by defined reprogramming factors. Oncogene (2014) 33:643–52.
doi:10.1038/onc.2012.614
162. Vander Heiden MG. Exploiting tumor metabolism: challenges for clinical
translation. J Clin Invest (2013) 123:3648–51. doi:10.1172/JCI72391
163. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al.
The metabolic profile of tumors depends on both the responsible genetic lesion
and tissue type. Cell Metab (2012) 15:157–70. doi:10.1016/j.cmet.2011.12.015
164. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, et al. Induced
pluripotent stem cells and embryonic stem cells are distinguished by gene
expression signatures.Cell StemCell (2009) 5:111–23. doi:10.1016/j.stem.2009.
06.008
165. Ciavardelli D, Rossi C, Barcaroli D, Volpe S, Consalvo A, Zucchelli M, et al.
Breast cancer stem cells rely on fermentative glycolysis and are sensitive to
2-deoxyglucose treatment. Cell Death Dis (2014) 5:e1336. doi:10.1038/cddis.
2014.285
166. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, et al. Glioma-
initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem
Cells Transl Med (2012) 1:811–24. doi:10.5966/sctm.2012-0058
167. Pacini N, Borziani F. Cancer stem cell theory and the Warburg effect, two sides
of the same coin? Int J Mol Sci (2014) 15:8893–930. doi:10.3390/ijms15058893
168. Hu J, Locasale JW, Bielas JH, O’Sullivan J, Sheahan K, Cantley LC, et al. Het-
erogeneity of tumor-induced gene expression changes in the human metabolic
network. Nat Biotechnol (2013) 31:522–9. doi:10.1038/nbt.2530
169. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glu-
cose deprivation contributes to the development of KRAS pathway mutations
in tumor cells. Science (2009) 325(5947):1555–9. doi:10.1126/science.1174229
170. Metallo CM, Gameiro PA, Bell EL, Mattaini KR,Yang J, Hiller K, et al. Reductive
glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature
(2011) 481(7381):380–4. doi:10.1038/nature10602
171. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic
glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc
Natl Acad Sci U S A (1994) 91:10625–9. doi:10.1073/pnas.91.22.10625
172. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al.
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.
J Clin Invest (2008) 118:3930–42. doi:10.1172/JCI36843
173. Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant
of cell type-specific glutamine independence in breast epithelia. PLoS Genet
(2011) 7:e1002229. doi:10.1371/journal.pgen.1002229
174. Salem AF, Whitaker-Menezes D, Lin Z, Martinez-Outschoorn UE, Tanowitz
HB, Al-Zoubi MS, et al. Two-compartment tumor metabolism: autophagy
in the tumor microenvironment and oxidative mitochondrial metabolism
(OXPHOS) in cancer cells. Cell Cycle (2012) 11:2545–56. doi:10.4161/cc.20920
175. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP.
Caveolin-1 and cancer metabolism in the tumor microenvironment: markers,
models, and mechanisms. Annu Rev Pathol (2012) 7:423–67. doi:10.1146/
annurev-pathol-011811-120856
176. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat
Rev Cancer (2008) 8:915–28. doi:10.1038/nrc2536
177. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiava-
rina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence
that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle
(2010) 9:3506–14. doi:10.4161/cc.9.17.12731
178. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides
S, et al. Ketones and lactate increase cancer cell “stemness,” driving recur-
rence, metastasis and poor clinical outcome in breast cancer: achieving per-
sonalized medicine via Metabolo-Genomics. Cell Cycle (2011) 10:1271–86.
doi:10.4161/cc.10.8.15330
179. Wu LE, Gomes AP, Sinclair DA. Geroncogenesis: metabolic changes during
aging as a driver of tumorigenesis. Cancer Cell (2014) 25:12–9. doi:10.1016/j.
ccr.2013.12.005
180. Feldman JL, Dittenhafer-Reed KE, Denu JM. Sirtuin catalysis and regulation.
J Biol Chem (2012) 287:42419–27. doi:10.1074/jbc.R112.378877
181. Mihaylova MM, Sabatini DM, Yilmaz ÖH. Dietary and metabolic control of
stem cell function in physiology and cancer. Cell Stem Cell (2014) 14:292–305.
doi:10.1016/j.stem.2014.02.008
182. Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory
for cancer chemoprevention by natural dietary compounds. J Nutr Biochem
(2011) 22:799–806. doi:10.1016/j.jnutbio.2010.11.001
183. Menendez JA, Joven J, Aragonès G, Barrajón-Catalán E, Beltrán-Debón R,
Borrás-Linares I, et al. Xenohormetic and anti-aging activity of secoiridoid
polyphenols present in extra virgin olive oil: a new family of gerosuppressant
agents. Cell Cycle (2013) 12:555–78. doi:10.4161/cc.23756
184. Pollak M. Potential applications for biguanides in oncology. J Clin Invest (2013)
123:3693–700. doi:10.1172/JCI67232
185. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC, Struhl
K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic
intermediates during cell transformation and NTPs in cancer stem cells. Proc
Natl Acad Sci U S A (2014) 111:10574–9. doi:10.1073/pnas.1409844111
186. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets
cancer stem cells, and acts together with chemotherapy to block tumor growth
and prolong remission.Cancer Res (2009) 69:7507–11. doi:10.1158/0008-5472.
CAN-09-2994
187. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory
response associated with cellular transformation and cancer stem cell growth.
Proc Natl Acad Sci U S A (2013) 110:972–7. doi:10.1073/pnas.1221055110
188. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Met-
formin and cancer: doses, mechanisms and the dandelion and hormetic phe-
nomena. Cell Cycle (2010) 9:1057–64. doi:10.4161/cc.9.6.10994
189. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J,
Menendez JA. Metformin against TGFβ-induced epithelial-to-mesenchymal
transition (EMT): from cancer stem cells to aging-associated fibrosis.Cell Cycle
(2010) 9:4461–8. doi:10.4161/cc.9.22.14048
190. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J,
Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer
initiating CD44+CD24-/low cells is sufficient to overcome primary resistance
to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget (2012)
3:395–8.

























































Menendez and Alarcón Cancer metabostemness
191. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J,
Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget
(2011) 2:896–917.
192. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS. Metformin represses
self-renewal of the human breast carcinoma stem cells via inhibition of
estrogen receptor-mediated OCT4 expression. PLoS One (2011) 6:e28068.
doi:10.1371/journal.pone.0028068
193. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco
S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer
epithelial cells treated with the anti-diabetic drug metformin: induction of
the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced
oncomiR miRNA-181a. Cell Cycle (2011) 10:1144–51. doi:10.4161/cc.10.7.
15210
194. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menen-
dez JA. Metformin and energy metabolism in breast cancer: from insulin
physiology to tumour-initiating stem cells. Curr Mol Med (2010) 10:674–91.
doi:10.2174/156652410792630625
195. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B,
Menendez JA. Metformin regulates breast cancer stem cell ontogeny by tran-
scriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle (2010) 9:3807–14. doi:10.4161/cc.9.18.13131
196. Vazquez-Martin A,Oliveras-Ferraros C,Del Barco S,Martin-Castillo B,Menen-
dez JA. The anti-diabetic drug metformin suppresses self-renewal and prolifer-
ation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast
Cancer Res Treat (2011) 126:355–64. doi:10.1007/s10549-010-0924-x
197. Vazquez-Martin A, López-Bonetc E, Cufí S, Oliveras-Ferraros C, Del Barco S,
Martin-Castillo B, et al. Repositioning chloroquine and metformin to elimi-
nate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011)
14:212–23. doi:10.1016/j.drup.2011.04.003
198. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Oliveras-
Ferraros C, Martin-Castillo B, et al. Metformin limits the tumourigenic-
ity of iPS cells without affecting their pluripotency. Sci Rep (2012) 2:964.
doi:10.1038/srep00964
199. Bednar F, Simeone DM. Metformin and cancer stem cells: old drug, new tar-
gets. Cancer Prev Res (Phila) (2012) 5:351–4. doi:10.1158/1940-6207.CAPR-
12-0026
200. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, et al. Metformin
kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.
Sci Rep (2012) 2:362. doi:10.1038/srep00362
201. Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, et al.
Metformin targets the metabolic achilles heel of human pancreatic cancer stem
cells. PLoS One (2013) 8:e76518. doi:10.1371/journal.pone.0076518
202. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S,
et al. Antidiabetic drug metformin prevents progression of pancreatic cancer
by targeting in part cancer stem cells and mTOR signaling.Transl Oncol (2013)
6:649–59. doi:10.1593/tlo.13556
203. Würth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, et al. Met-
formin selectively affects human glioblastoma tumor-initiating cell viability:
a role for metformin-induced inhibition of Akt. Cell Cycle (2013) 12:145–56.
doi:10.4161/cc.23050
204. Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, et al. Met-
formin selectively targets tumor-initiating cells in ErbB2-overexpressing breast
cancer models. Cancer Prev Res (Phila) (2014) 7:199–210. doi:10.1158/1940-
6207.CAPR-13-0181
205. Riscuta G, Dumitrescu RG. Nutrigenomics: implications for breast and colon
cancer prevention. Methods Mol Biol (2012) 863:343–58. doi:10.1007/978-1-
61779-612-8_22
206. Ferguson LR, Schlothauer RC. The potential role of nutritional genomics tools
in validating high health foods for cancer control: broccoli as example. Mol
Nutr Food Res (2012) 56:126–46. doi:10.1002/mnfr.201100507
207. Levesque JP, Winkler IG, Rasko JE. Nichotherapy for stem cells: there goes the
neighborhood. Bioessays (2013) 35:183–90. doi:10.1002/bies.201200111
208. Lundstrom K. Past, present and future of nutrigenomics and its influence on
drug development. Curr Drug Discov Technol (2013) 10:35–46. doi:10.2174/
1570163811310010006
209. Steinhauser ML, Bailey AP, Senyo SE, Guillermier C, Perlstein TS, Gould AP,
et al. Multi-isotope imaging mass spectrometry quantifies stem cell division
and metabolism. Nature (2012) 481:516–9. doi:10.1038/nature10734
210. Steinhauser ML, Lechene CP. Quantitative imaging of subcellular metabolism
with stable isotopes and multi-isotope imaging mass spectrometry. Semin Cell
Dev Biol (2013) 24:661–7. doi:10.1016/j.semcdb.2013.05.001
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 03August 2014; accepted: 07 September 2014; published online: 29 September
2014.
Citation:Menendez JA andAlarcón T (2014)Metabostemness: a new cancer hallmark.
Front. Oncol. 4:262. doi: 10.3389/fonc.2014.00262
This article was submitted to Molecular and Cellular Oncology, a section of the journal
Frontiers in Oncology.
Copyright © 2014 Menendez and Alarcón. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org September 2014 | Volume 4 | Article 262 | 21
